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Chapter 1. General Introduction 

General Introduction 
Bladder Cancer 
Anatomy and histology of the normal bladder 
The bladder is a hollow organ in the small pelvis. It stores urine that is produced when the 
kidneys filter the blood. Four different layers, the epithelium, lamina propria, muscularis, and 
connective tissue, define the bladder wall. The epithelium consists of 7 to 10 cell layers and 
rests on a basal lamina synthesized by epithelial and mesenchymal cells (Figure 1). The 
thickness of the epithelial cell layer and the lamina propria depends on the degree of 
distension of the bladder. The cells of the epithelium are referred to as transitional cells. They 
line the urinary tract starting at the kidney, down the ureter, into the bladder and most of the 
urethra. Their shape varies between cubical and flat. The latter cells form the barrier between 
urine and the epithelium. Because of their large fiat morphology these superficial cells are 
sometimes named umbrella cells. The muscle coat of the bladder is also referred to as the 
detrusor muscle. It allows the bladder to get larger and smaller as urine is stored or emptied. 
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Figure 1. Histology of the bladder urothelium. Drawing from Gray's Anatomy, 1918. 
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Epidemiology 
Bladder cancer is the eleventh most frequent cancer worldwide, but more common in 
Western Europe and the United States, while Japan has a lower incidence. In the 
Netherlands, approximately 2550 new cases present each year. Of these patients, 1200 will 
die from the disease (190, 191). The male-to-female sex ratio is at least 3:1. This can in part 
be explained by the gender difference in smoking behaviour and occupational exposure (see 
Risk Factors). The 5-year survival rate is approximately 50%, being high in local, superficial 
disease (92.8%) intermediate in locally invasive disease (48.3%) and low in metastasized 
disease (5.9%) (10,130) 
Histological subgroups 
More than 90% of bladder tumors originate from the transitional cells lining the urinary tract. 
Many lower-grade tumors are papillary, and the cells covering its papillae are similar in 
appearance to those of the surrounding uninvolved urothelium. Other types of bladder cancer 
include squamous cell carcinoma and adenocarcinoma. These tumors constitute about 1 % of 
all bladder tumors, and show a male predominance as well. 
Carcinoma in situ is a flat, non-papillary, non-invasive, histopathologically anaplastic 
epithelium. Carcinoma in situ may present as a localized lesion adjacent to a superficial 
papillary or an invasive tumor, as a diffuse urothelial disease concomitant with macroscopic 
tumors, as a primary focal lesion in asymptomatic patients, or as symptomatic, diffuse, or 
multifocal lesions of the urothelium, not associated with macroscopic tumors at the time of 
diagnosis. 
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Table 1. Bfaddercancerstages. 
Tumor characteristics Stage 
Carcinoma in situ TIS 
Papillary tumor limited to mucosa Ta 
Invasion lamina propria T1 
Superficial muscle Invasion T2 
Deep muscle and/or fat invasion T3 
Invasion contiguous viscera T4 
Growth 
abc de 
a, urothefium; b, lamina propria; c, muscularis propria; d, surrouding fat tissue; e, surrounding organs 
Genera! Introduction 
Grading and staging 
Three grades of urothelial carcinoma are recognized according to the WHO. Grade 1 
represents well-differentiated papillary tumors with limited atypia and mitoses. At the other 
end, Grade 3 lesions show a marked disordered arrangement of the cell layers, cell size, and 
number of mitoses. Tumor grade appears to correlate Significantly with prognosis. The higher 
the grade of the diagnosis, the higher the mortality within two years. 
The staging of bladder cancer is based on the depth of invasion (Table 1). Tumors 
limited to the mucosa or lamina propria are often referred to as superficial, while tumors 
growing into the muscle and further are named invasive. Invasive bladder tumors tend to 
spread rapidly to the regional lymph nodes and then into adjacent structures. 
Clinical Presentation 
Patients with bladder cancer usually present with hematuria (blood in the urine) that is 
sometimes only visible under the microscope (microscopic hematuria). Other manifestations 
include bladder irritability and symptoms of urethral obstruction. Frequently the diagnosis of 
bladder cancer is delayed because bleeding is intermittent or attributed to other causes such 
as urinary tract infection, benign tumors, or bladder stones. Voided urine cytology is 
performed on a Papanicolaou stained smear of cells present in the urine. These can include 
infiammatory (blood) cells and cells previously lining the urinary tract that are exfoliated into 
the urine. Urinary cytology is highly specific, but has a low sensitivity. This means that if the 
urinary cytology is positive, transitional cell cancer of the urothelium is almost certainly 
present. But cytological examinations may be negative in up to half of patients with bladder 
cancer; thus, a negative smear does not rule out bladder cancer. Recently, several 
companies have started to offer dipstick tests of the urine to check for the presence of 
bladder cancer. Another possibility would be to look for DNA aberrations in cells collected 
from voided urine. 
Superficial bladder cancer tends to recur frequently after their surgical removal; if this 
happens, it most often recurs as another superficial cancer. At presentation, approximately 
80% of TCCs of the bladder are superficial papillary lesions (Ta/T1), the majority of which do 
not invade despite the common development of recurrences at the same or different sites in 
the bladder over a period of many years. For most of the 20% of tumors that are muscle 
invasive (T2) or metastatic (N+, M+) at the time of presentation, there is apparently no 
superficial papillary precursor lesion and these tumors may progress rapidly (130). 
Treatment 
Bladder cancer may be treated with surgery, biological therapy, radiation therapy, or 
chemotherapy. The choice of treatment depends on its stage and grade, particularly if, or 
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how deeply, the cancer has invaded the bladder wall. The urethra and bladder are inspected 
with a cystoscope to investigate the tumor size, number of tumors, and their location. 
Patients with low-grade superficial bladder cancer may be treated with a procedure called 
transurethral resection (TUR). A tool with a small wire loop on the end is used to remove the 
cancer (biopsy). Biopsies of normal-appearing bladder lining are performed to check for 
microscopic cancer that would otherwise be missed. Generally, this is followed by periodic 
cystoscopy, and cytologic evaluations. 
Curative treatment of invasive bladder cancer comprises radical cystectomy, by which 
the entire bladder is removed, including nearby lymph nodes, and any surrounding organs 
that contain cancerous cells. For invasive cancers that appear to be limited to the bladder 
(stages T2-3), complete surgical removal of the bladder provides the best chance of a cure. 
When complete surgical removal of the bladder is performed, usually, a segment of small 
bowel is used to transfer urine directly from the kidneys and ureters through a stoma on the 
skin and into an external collection bag. 
Patients with multiple tumors, high~grade tumors, carcinoma in situ or tumor 
penetration into the lamina propria are at high risk for tumor recurrence and progression. 
They are candidates for intravesical therapy with bacillus Calmette-Guerin (BCG), mitomycin, 
doxorubicin or thiotepa. Treatment with BCG involves plaCing a solution of BCG, a substance 
that stimUlates the immune system, into the bladder for about 2 hours before the patient is 
allowed to empty the bladder by urinating. 
In radiation therapy, high-energy rays are used to kill cancer cells. Like surgery, 
radiation therapy is local therapy. When bladder cancer has spread to other organs, radiation 
therapy may be used to relieve symptoms caused by the cancer. Radiation may come from 
outside the body (external radiation) or from a radiation implant, placed directly into the 
bladder (internal radiation). 
Chemotherapy may be used alone or after TUR to treat superficial bladder cancer. 
Systemic chemotherapy may also be used to manage advanced bladder cancer, when 
cancer cells have deeply invaded the bladder and spread to lymph nodes or other organs. 
(130) 
Risk Factors 
Bladder cancer was one of the earnest cancers in which carcinogens were found to playa 
role in causing the disease. The most important known risk factor for bladder cancer is 
cigarette smoking. Cigarette smokers develop bladder cancer two to three times more often 
than non-smokers (28, 29, 119). Smoking does not only increase the risk for transitional cell 
carcinoma, but also for squamous cell carcinoma and adenocarcinoma of the bladder. 
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Smoking is estimated to be responsible for 25-60% of the bladder cancers in industrialized 
countries. 
Occupational exposure to a certain class of organic chemicals called aromatic amines 
(beta-naphthylamines, xenylamine, 4-nirtobiphenyl, benzidine) is a well-established risk 
factor. Bladder cancer due to aromatic amine exposure has been documented in the textile, 
leather, rubber, dye, paint, hairdressing, and organic chemical industries. A period of 5 to 50 
years may follow the exposure of carcinogenic agents and the diagnosis of bladder cancer. 
Infection with Schistosoma haematobium, a parasite commonly encountered in Asia, 
Africa and South America, has been linked to bladder cancer. The eggs of the paraSites are 
deposited in the bladder wall, and the morbidity of the disease is associated with chronic 
infection. Due to this infection, the proliferation rate of the urotheJium is much higher. The 
tumors formed are mainly squamous cell carcinomas and adenocarcinomas. 
Other factors that may contribute to the development of bladder cancer include 
bladder treatment with the anticancer drugs chlornaphazine or cyclophosphamide, long-term 
use of painkillers containing the drug phenacetin, recurrent urinary tract infections and stasis, 
dietary factors, tobacco products other than Cigarettes (e.g., pipes and cigars), and genetic 
susceptibility. 
Genetic susceptibility 
In response to exposure to environmental agents that are toxic or mutagenic, organisms 
have evolved complex mechanisms by which they can protect themselves. This involves the 
expression of enzymes active in the metabolism and detoxification of the foreign chemicals. 
The best characterized of these enzyme systems are the cytochrome P450s, the glutathione-
S-transferases (GSTs) and the N-acetylation enzymes (NATs). Genetic polymorph isms with 
well defined associated phenotypes have now been characterized in these genes (162). 
Indeed, many of these polymorph isms have been associated with a difference in the ability to 
detoxify substances that may otherwise act as carcinogens. This may render an individual 
more at risk for developing cancer. In the case of bladder cancer, both GST and NAT 
polymorphisms are implicated in an increased susceptibility. 
Aromatic amines may be inhibited in their carCinogenic ability by acetylation. The 
acetylation speed in different individuals can, by nature, be slow or rapid. The slow N-
acetylation genotype (NAT2) is a susceptibility factor in occupational and smoking-related 
bladder cancer (85, 142). The glutathione-S-transferase Mu1 enzyme (GSTM1) detoxifies 
arylepoxides which are formed after exposure to certain polycyclic aromatic hydrocarbons 
and possibly aromatic amines. According to the study of both Mungan et a/. and Georgiou et 
al. (51, 121), individuals with the GSTM1 null genotype carry a substantially higher risk for 
bladder carcinogenesis. The GSTM1 null genotype is not associated with more aggressive 
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disease in terms of tumor grade, although there is a correlation between this genotype and 
stage of the disease. 
Cancer genetics 
Chromosomes and cancer 
Chromosomal analysis of cancer cells has yielded a huge amount of information about the 
nature and incidence of chromosome abnormalities (74, 163). These abnormalities include 
numerical and structural changes. Numerical chromosomal changes lead to aneuploidy, 
which means any deviation of the normal set of 46 chromosomes. Polyploidy means the 
presence of whole sets of chromosomes in excess to the normal set of 46. Aneuploidy can 
be caused by non-disjunction, the failure of chromosomes to separate properly during the 
early stages of mitosis or meiosis. Aberrations in chromosome structure result from the 
breakage and reunion of chromosome segments and can involve one or more 
chromosomes. They can be divided in deletions, duplications, inversions, translocations, 
rings, and fragile sites. Chromosome breaks can occur from spontaneous errors in 
replication, crossing over, mutations in genes that normally repair breaks, and environmental 
agents such as ultraviolet light, radiation, chemicals, or viruses. 
Oncogenes and tumor suppressor genes 
Tumors arise from changes in the processes that control growth, division and mortality of 
cells. These changes are caused by mutations in oncogenes, tumor suppressor genes, or 
genes that are involved in DNA repair. Oncogenes were first discovered in transforming RNA 
viruses. They are derived from normal cellular proto-oncogenes with roles in normal growth 
and proliferation. When these genes are activated by a gain-of-function mutation, they may 
function as an oncogene and their products will for instance increase cell proliferation or 
inhibit cell death. Different types of oncogenes can be distinguished, based on their biological 
function, including growth factor receptors, transcription factors, or genes involved in protein 
phosphorylation or cell cycle regulation. Over 40 different oncogenes have been identified so 
far. Activation of a proto-oncogene can occur by a pOintmutation, chromosomal translocation 
or by amplification of the gene. 
Loss of growth suppression requires inactivation of both copies of a tumor suppressor 
gene for a phenotypic effect (Knudson's two-hit hypothesis, Figure 2) (91-93). Many different 
genetic incidents can eliminate both copies of a gene. Inactivation of one allele is often 
brought about by small sequence alterations like pOint mutations or small deletions. 
Inactivation of the other allele can be the result of loss of genetic material due to inaccurate 
chromosome segregation. In this case, the second copy of the gene, and usually flanking 
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regions of its chromosome as well, are either totally deleted or replaced by a copy of the 
corresponding region of the first defective chromosome. 
Inherited predisposition 
Normal tissue Tumour 
Sporadic tumour 
Normal tissue Tumour 
Figure 2. Knudson's two~hit hypothesis explained by the retinoblastoma model of tumorigenesis. + wild type allele, 
rb mutated allele. In patients with a germine mutation of the retinoblastoma gene only one mutation is necessary 
for the cell to become homozygous rb. In sporadic tumors, two mutations are required for the cell to become 
homozygous for the rb mutation. From: Hodgson & Maher, 1993 (69). 
LOH in the cells of a tumor provides the basis for a method by which tumor 
suppressor genes can be identified and cloned, Tumor allelotyping (in analogy to 
karyotyping) is the analysis of all 23 pairs of human chromosomes for regions of LOH, The 
first allelotype was performed on colorectal carcinoma by Vogelstein et aI, in 1989 (192), 
Allelotypes have been published for most of the major types of cancer, To date, despite the 
fine mapping of multiple common regions of deletion in sporadic tumors, only a small number 
of tumor suppressor genes mapped in this way have been authenticated. These include 
DPC4 (65), and PTEN (102, 167), both of which have been found via a homozygous 
deletion. The usual heterozygous combination of maternal and paternal alleles of genes in 
that chromosomal region is lost (loss of heterozygosity or LOH, see Microsatellite instability 
and LOH), A tumor suppressor gene can also be inactivated by a small homozygous deletion 
within the gene, or extending only a short distance into DNA flanking the target gene, 
Another mechanism is de novo methylation of cytosine residues at CpG dinucleotides in the 
5' CG-rich promoter region of genes, This leads to transcriptional silencing, These 
mechanisms are depicted in Figure 3. Several tumor suppressor genes have been identified 
to date that conform to the two-hit modeL A list of these genes is given in Table 2, 
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Figure 3. Model for the inactivation of tumor suppressor genes. +, wild type allele, rb, mutated allele, alb and Cld 
are polymorphisms at two arbitrary marker loci either side of the tumor suppressor gene. The pair of 
chromosomes from the normal cell are heterozygous at both loci. The tumor either lost the tumor suppressor 
gene function due to a homozygous deletion or is homozygous for the rb mutation. In addition there is loss of 
heterozygosity at the marker loci in the tumor tissue unless it is a localized event. Note that the allele loss affects 
the chromosome with the wild type allele. Adapted from Hodgson & Maher, 1993 (69). 
Chromosomal instability 
Loss of a single tumor suppressor gene - even loss of both copies of the gene - is usually not 
sufficient by itself to cause cancer. In order for a tumor to develop, at least 3 to 6 mutations 
are needed in oncogenes or tumor suppressor genes (193). One way of reaching this 
number of mutations is by raising the mutation frequency. Cancer cells often display an 
enormous variability in the size and shape of their nuclei and in the number and structure of 
their chromosomes; in fact, abnormal nuclear morphology is one of the key features used by 
pathologists to diagnose cancer. Cancer cells grown in culture often have an unstable 
karyotype: genes become amplified or deleted and chromosomes become lost, duplicated, or 
translocated with a much h'lgher frequency than in normal cells in culture. This chromosomal 
variability suggests that these celis have some defect in the control of chromosome 
replication, repair, recombination, or segregation, i.e. they have an unstable genome (101). 
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Tabfe 2. Tumor suppressor genes and associated human cancers. 
Adapted from Macleod, CurrOpin Genet Dev 10:81-93,2000 (110). 
Tumor Human Gene function Human tumors associated Associated cancer 
suppressor chromosomal with sporadic mutation syndrome 
gene location 
RB1 13q14 Transcriptional regulator Retinoblastoma, Familial 
of cell cycle osteosarcoma retinoblastoma 
WT1 11 p13 Transcriptional regulator Nephroblastoma Wilms tumor 
TP53 17q11 Transcriptional regulator! Sarcomas, breast/brain Li-Fraumeni 
growth arrest/apoptosis tumors 
NF1 17q11 Ras-GAP activity Neurofibromas, Von 
sarcomas, gliomas Recklinghausen 
neurofibromatosis 
NF2 22q12 ERM protein! Schwannomas, Neurofibromatosis 
cytoskeletal regulator meningiomas type 2 
VHL 3p25 Regulates proteolysis Hemangiomas, renal, Von-Hippel Lindau 
pheochromocytomas 
APC 5q21 Binds!regulates ~- Colon cancer Familial 
catenin activity adenomatous 
polyposis 
INK4A 9p21 P16 cdki for cyclinDJ Melanoma, pancreatic Familial melanoma 
cdk4/6; p19 binds mdm2, cancer 
stabilizes p53 
PTC 9q22.3 Receptor for sonic Basal cell carcinoma, Gorlin syndrome 
hedgehog medulloblastoma 
BRCA1 17q21 Transcriptional Breast/ovarian tumors Familial breast 
regulator/DNA repair cancer 
BRCA2 13q12 Transcriptional Breast/ovarian tumors Familial breast 
regulator/DNA repair cancer 
DPC4 18q21.1 Transduces TGF-f1 Pancreatic, colon, Juvenile polyposis 
signals hamartomas 
FHIT 3p14.2 Nucleoside hydrolase Lung, stomach, kidney, Familial clear cell 
cervical carcinoma renal carcinoma 
PTEN 10q23 Dual specificity Glioblastoma, prostate, Cowden syndrome, 
phosphatase breast BZS, LDD 
TSC1 9q34 Cell-cylce regulator Renal, hamartomas Tuberous sclerosis 
TSC2 16 Cell-cycle regulator Renal, brain tumors Tuberous sclerosis 
NKX3.1 8p21 Homeobox protein Prostate Familial prostate 
carcinoma 
LKB1 19p13 Serine/threonine kinase Hamartomas, colorectal, Peutz..Jeghers 
breast 
ECAD 16q22,1 Cell adhesion regulator 6reast, colon, skin, lung Familial gastric 
carcinoma cancer 
MSH2 2p22 MutS homologue, Colorectal cancer HNPCC 
mismatch repair 
MLH1 3p21 MutL homologue, Colorectal cancer HNPCC 
mismatch repair 
PMS2 2q31 mismatch repair Colorectal cancer HNPCC 
PMS2 7p22 mismatch repair Colorectal cancer HNPCC 
MSH2 2p16 mismatch repair Colorectal cancer HNPCC 
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Currently, two different pathways to tumorigenesis are thought to exist (84), The first pathway 
involves gatekeeper genes. These genes are directly controlling cellular proliferation. 
Examples include the genes responsible for colon cancer, retinoblastoma and 
neurofibromatosis. The second pathway is represented by caretaker genes. These genes 
maintain the integrity of the genome. They sustain the intracellular machinery governing 
replication, recombination, and repair of DNA that is caused by, e.g., mutagens in the 
environment. People with the rare genetic disorder xeroderma pigmentosum, for example, 
have a defect in the system of enzymes required to repair the type of damage done to DNA 
by ultraviolet irradiation; as a result, the slightest exposure of the skin to sunlight is liable to 
provoke skin cancers (172, 200). A more general predisposition to cancer due to faults in 
DNA repair and replication occurs in the relatively common HNPCC syndrome, and in 
Bloom's syndrome, Fanconi's anemia, and ataxia-telangiectasia (189). Inactivation of a 
caretaker gene would not directly promote tumor initiation, but increase the mutation 
frequency, resulting in genetic instability and mutations in other genes, for instance 
gatekeeper genes, 
Microsatellite instability and LOH 
Microsatellites 'or short tandem repeat polymorph isms (STRs) are short stretches of 
nucleotide sequences, usually repeated between 15 and 30 times. The repeated sequences 
are 2 to 5 nucleotides long. Microsatellites belong to a family of repetitive non-coding DNA 
sequences comprising satellites (5-100 bpi, minisatellites (15-70 bpi and microsatellites. 
Between 35,000 and 100,000 different microsatellites are present in the human genome, a 
marker density of approximately one microsatellite every 100,000 bp. They are not uniformly 
spaced along chromosomes but tend to be underrepresented in subtelomeric regions. The 
most frequent occurring repeat motif is the (CA)n dinucleotide sequence. 
No definite function can be ascribed to microsatellite sequences. The short size and 
high variability of microsatellite markers made them easy to type with the polymerase chain 
reaction (PCR). This has had a profound effect on genome analysis and the construction of a 
physical map of the human genome. An application of such a map is the linkage analysis, 
which tests whether a chromosomal region is correlated with transmission of a certain 
hereditary disease within a pedigree. A polymorphism is considered informative or 
heterozygous if the number of repeats differs between the two different chromosomes of an 
individual. The informativity of these polymorph isms depends on the number of repeats. The 
more variation in the stretch of repeats, the higher the chance that both chromosomes have 
a different repeat length. This makes them useful markers to study heterozygosity of 
genomes (95). Another application of these markers is to detect loss of heterozygosity in 
tumor DNA. This is explained in Figure 4. 
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Figure 4. Detection of loss of heterozygosity or microsate/fite instability in tumor DNA. A a microsatelfite marker is 
amplified via unique peR-primer sequences on either site of the repeat. The length of the amplified band depends 
on the number of repeats (gray and black boxes). B, an example of the possible outcomes. N, normal DNA, T, 
tumor DNA. The first two individuals are heterozygous without loss, the third has loss of the lower allele in the 
tumor DNA, the fourth shows microsatelfite instability represented by an extra band above the normal alfele 
bands, the fifth is not informative (homozygous) because both alleles have the same length. 
DNA polymerases are less able to process through repetitive sequences and therefore 
slippage is more likely to happen in these regions. The stable transmission of repeat size is 
no longer guaranteed when mutations are present in genes responsible for the detection and 
repair of replication errors, like the hMSH2 or hMLH1 genes (9). Tumors due to such 
mutations are called RER+, replication error positive. These tumors have a relatively normal, 
diploid karyotype and their cell cycle checkpOints are intact (11, 48). RER+ tumors show 
microsatellite instability (MIN) which means that the length of the microsatellites may become 
altered in cells of RER+ tumors (Figure 4). 
Clonalily versus field cancerization 
Some cancer types, like bladder cancer, head and neck cancer and colon cancer, present 
themselves as multifocal. There has been considerable debate about whether tumors arise 
from a single mutated cell (clonal) as a multistep process, or whether there can be a process 
named field cancerization. Clonal development of multiple cancers is thought to occur 
through a series of recognizable stages, followed by spread and outgrowth of mutated 
progeny. Exposure of an entire field of tissue to repeated carcinogenic insults could give rise 
to multiple unrelated polyclonal tumors (50). It is not unlikely to think of a polyclonal process 
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in these multifocal cancer types, since environmental exposure could provide a constant 
mutation causing agent. To discriminate between the two possibilities, several groups have 
looked at X-chromosome inactivation patterns (46, 122) and the presence of specific 
mutations in for instance the TP53 gene at chromosome 17p (198). When the same 
mutations or X-inactivation are observed in all multifocal tumors from one patient, the tumors 
are considered monoclonal. Another method that has been used to study clonalily is MIN 
(112). Identical microsatellite alterations detected in multifocal tumors, recurrences, or 
metastases can serve as evidence for their clonal relation. 
It is now widely accepted that most multifocal tumor types are monoclonal in origin, 
arising from a mutation or series of mutations in a single cell and its descendants. Possible 
exceptions are tumors of the aerodigestive tract, thought to be caused by chronic exposure 
to alcohol and tobacco (182,198). 
Genetic aberrations in bladder cancer 
Cytogenetic studies and CGH in bladder cancer 
Structural analyses of the genome changes in bladder cancer include cytogenetic studies, 
identification of deletions by LOH or homozygous deletion analysis, and comparative 
genomic hybridization (CGH) (79). 
Cytogenetic studies of bladder cancer have given indications of the possible locations 
of relevant tumor suppressor genes (52, 135, 146). Monosomy 9 was described as the sole 
cytogenetic abnormality in some near diploid bladder tumors, sometimes accompanied by 
trisomy 7 and trisomy 10 (114). Other seemingly unique alterations on chromosome 9 
include an interstitial del(9)(q11q21.2) (8). Another indication for the involvement of genes on 
chromosome 9 came from chromosome transfer studies. Following introduction of an intact 
chromosome 9 into bladder cancer cell lines, only clones with a rearranged chromosome 9 
could be propagated in vivo (104, 20S). 
CGH analysis of bladder cancer showed losses on chromosome 2q, 3p, 4q, Sq, 11 p, 
11q, 8p, 9, 10q, 12q 17p, and 18q in more than 20% of the tumors (78, 159). Gains of DNA 
sequences were most often found at chromosomal regions distinct from the locations of 
currently known oncogenes, The bands involved in more than 10% of the tumors were 8q21, 
13q21-q34. 1q31, 3p22-24, 3q24-q26, 1p22, 10p13-14, 12q13-1S, 17q22-23, 18p11, and 
22q11-13 (78,196). 
Oncogenes and tumor suppressor genes that playa role in bladder cancer 
Several genes that are known to be altered in other tumor types have been studied for their 
involvement in bladder cancer. These include the oncogenes HRAS, ERBB2, and MYC, and 
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the tumor suppressor genes TP53, CDKN2A, RB, and PTEN. The characteristics of these 
genes are listed in Table 3. 
HRAS is part of a family of genes whose products are involved in the transduction of 
mitogeniC signals. HRAS mutations are reported infrequently in bladder tumors, with 
mutation frequencies varying between 6% (90) and 44% (47). ERBB2 codes for an epidermal 
growth factor receptor-like protein and is amplified and overexpressed in 10-26% of bladder 
tumors (72, 126). MYC overexpression is sometimes found in bladder tumors, especially in 
tumors of higher grade (27, 148). 
FGFR3 belongs to a family of four receptors that together contain the most frequent 
germ line mutations in humans. More than 75 different mutations have been recorded, which 
account for more than seven skeletal syndromes, including achondroplasia, 
hypochondroplasia, thanatophoric dysplasia, and Muenke coronal craniosynostosis (80, 134, 
180). All the mutant phenotypes cause a gain-of-function by receptor activation through three 
major mechanisms: receptor dimerization, kinase activation, and increased affinity for FGF. 
Paradoxically, the consequence of receptor activation is inhibition of chondrocyte cell growth 
through signaling pathways that are cell-type specific. The FGFR3 gene is located on 
chromosome 4p16, and is activated by mutation in approximately 30% of bladder tumors 
(20). The role of the receptor in urothelial cells has yet to be established. Research in our lab 
so far suggests that screening for receptor mutations can identify patients with a lower 
recurrence rate of superficial tumors (183). 
TP53 has been mapped to chromosome 17p13 and encodes a 53 kD protein, which 
is a transcription factor involved in cell-cycle regulation. The protein functions as a check 
point arresting cells in G1 when the genome is damaged. This allows cells to repair the DNA 
damage. The protein also induces apoptosis. Mutations in TP53 will result in inactivation of 
the product and an increase in genetic alterations due to lack of DNA damage control. 
Genetic alterations of TP53, such as mutations, homozygous deletions and structural 
rearrangements are frequent events in bladder cancer (97, 203). With immunohistochemical 
staining, nuclear overexpression is often seen in tumors carrying TP53 mutations, This can 
be explained by the fact that the presence of a mutation increases the half-life of the protein 
4 to 20 times. Nuclear overexpression of the protein p53 can serve as a prognostic factor 
and is significantly related to tumor progression (41, 66, 137, 147, 177, 197). 
The CDKN2A gene was identified as a candidate gene on chromosome 9p. 
Homozygous deletion mapping using quantitative duplex PCR showed that CDKN2A andlor 
the adjacent gene CDKN2B is the likely target of the 9p21 deletion in bladder cancer (204). 
Others have shown that point mutation and other small sequence changes in CDKN2A are 
rare in bladder cancer (13, 127, 204) The retained allele of the gene is in some bladder 
tumors silenced by methylation (54, 57). The identification of homozygous deletion as the 
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predominant mechanism of inactivation led to the hypothesis that inactivation of both 
CDKN2A and CDKN2B contributes to bladder cancer development and that a homozygous 
deletion provides an efficient means of inactivating more than one adjacent gene (128, 171), 
The RB gene is located on chromosome 3 and codes for the RB protein, which 
functions as an important cell cycle checkpoint, the restriction point. Mutations that inactivate 
the RB gene were found in approximately 30% of bladder tumors, mostly of high stage and 
grade (15, 118). 
Table 3. Oncogenes and tumor suppressor genes altered in bladder cancer. 
Gene Involved (%) Clinical association References 
HRAS 6-44 Grade 47,90 
ERBB2 10-14 Grade, stage, recurrence 73,115,126,150,179,194,197 
MYC Grade, stage 148 
FGFR3 30 Lower recurrence rate 20, 183 
RB 30 High stage, progression, reduced survival 15,31,106.118 
TP53 10-70 Grade and stage, progression, reduced survival 63,151,156,166,174,199,203 
CDKN2A 20-45 ? 13,54,56,127,166,204,205 
PTEN 10-30 ? 4, 14 
Adapted from Knowles, Br J Urollnt 84: 412-427, 1999 (86). 
PTEN is located on chromosome 10q23 (102, 167). It is inactivated in several types of 
cancer including melanoma, prostate cancer and endometrial carcinoma. A search for 
mutations of PTEN in bladder tumors has yielded only a very small number of mutations and 
homozygous deletions (14), a frequency much lower than the frequency of LOH on 10q. It is 
possible that another gene in the same region is involved. However, the finding of intragenic 
homozygous deletions in bladder tumor cell lines (4, 118) indicates that PTEN plays a critical 
role in at least some cases. 
Loss of heterozygosity in bladder cancer 
To define the smallest region of deletion on a chromosome arm, a large number of tumor 
samples is used for microsatellite-based LOH and homozygous deletion analysis at low 
marker density. When the regions found in these tumors are combined, the resulting region 
of overlap is used to pinpoint the starting pOint of an attempt at cloning the gene involved. In 
1994, an allelotype analysis was published based on a series of primary TCCs using 90 
markers (88). About 60% of these tumors analyzed were superficial (pTa/T1). The most 
frequent losses were on chromosome 9 (9p, 51%; 9q, 57%). Other chromosome arms with 
frequent deletions were 11p (32%), 17p (32%), 8p (23%) 4p (22%) and 13q (15%). LOH on 
17p and 13q is commonly associated with mutational inactivation of the retained copy of the 
TP53 or RB genes, respectively (15, 203). LOH on all of these chromosome arms except 
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chromosome 9 is associated with high tumor grade and stage. Other studies have 
subsequently identified deletions on 3p (13S), 10q (21,77), 1Sq (12), and 14q (22) (Table 4). 
Carcinoma ;n s;tu (CIS) is regarded as the most likely precursor lesion for invasive 
TCC. If so, the genetic aberrations identified in CIS are expected to be similar to those found 
in invasive Tee, but not superficial. A partial allelotype study of CIS using 29 markers on 13 
chromosome arms (3p, 4p, 4q, 5q, Sp, 9p, 9q, 11p, 11q, 13q, 14q, 17p and 1Sq) has been 
reported (143). LOH of chromosome 9 was frequent (77%), as was LOH on Sp (65%), 17p 
(60%), 13q (56%), 11p (54%), 4q (52%) and 14q (70%). These frequencies, with the 
exception of chromosome 9 loss, are significantly higher than those found in superficial 
papillary TCC and resemble those found in invasive bladder cancer. This could indicate that 
CIS, although classified as a stage Ta lesion, represents a potentially aggressive entity. 
A partial allelotype of squamous cell carcinomas (SeC) from patients with a history 
schistosomiasis revealed LOH on all chromosome arms studied (3p, 4p, 4q, Sp, 9p. 9q, 11 p, 
11q, 13q, 14q, 17p, 1Sq) (154). The most frequent regions of LOH were 9p (65%), 17p 
(58%), 3p (40%), 9q (39%) and 8p (37%). The most striking difference between this group of 
sces and Tees was the high frequency of 9p LOH in the region of the CDKN2A gene (65%) 
and the relatively lower frequency of 9q LOH (39%). This suggests that a 9p gene, possibly 
CDKN2A, which is also implicated in TCC, may contribute to the development of the majority 
of schistosomiasis-associated bladder tumors and that a gene(s) on 9q plays a less 
important role. 
A common region of deletion of about 750 kb was found close to the Huntington 
disease gene at 4p16.3 (39), together with a larger more centromeric region of deletion, a 
region at 4p15 and a region on 4q (136). The proximity of the 4p16.3 region of deletion to the 
HD gene provided many probes and allows mapping with a resolution of 30-40 kb. One 
candidate gene located within the region is the gene SH3BP2. Detailed mutation analysis 
failed to identify coding sequence mutations in bladder cell lines or primary tumors (6). 
Allelotype analysis identified 8p LOH in approximately 23% of TCCs. Apart from a 
TP53 mutation, LOH of 8p is the most frequent and specific alteration in muscle-invasive 
bladder tumors. Preliminary mapping showed that the deleted region was also deleted in 
several other tumor types, including prostate, which shows 70-S0% 8p LOH (S9). At least 
three regions are involved in the bladder, a large region at Sp21-22 encompassing two 
regions of deletion defined in prostate cancer, and two smaller, more proximal regions at 
Sp12-21, both contained within a third region defined in prostate cancer (111,170). Most 
bladder tumors with 8p LOH, however, seem to have lost the entire chromosome arm (S9, 
170). Several candidate genes mapped within these Sp regions, including the POLB and 
PPP2CB genes, were tested with mutation analysis but revealed no mutations in bladder 
tumors or cell lines (42). 
25 
Chapter 1 
Table 4. Candidate regions for TSGs involved in TCC of the bladder. 
Chrom Regions Association with References 
(genes) tumor grade/stage 
3 3p High grade and stage 138 
4 4p16.3,4pcen-p14 All stages/grades 39 
4p15 High grade and stage 136 
4q33-34 High grade and stage 136 
8 8p21.1-pter High stage 170 
8p".2-'2 High stage 170 
9 9p21 (CDKN2A) All stages/grades 18,36,127,204 
9q13-31 All stages/grades 13,60 
9q32-33 All stages/grades 160 
9q34 (TSC1) All stages/grades 60,64,160 
10 10q23 (PTEN) High stage 21,77 
11 11p15 High grade 44, 155, 176 
11q13-23.2 High grade 155 
13 13q (RS) High grade and stage 15 
14 14q12 High stage 22 
14q32.1-32.2 High stage 22 
17 17p13 (TP53) High grade and stage 63,125,166,176,203 
18 18q21.3-qter High stage 12 
Deletions of chromosome 11 can be detected in around 40% of TCCs (44, 176), and LOH of 
11p is associated with higher tumor grade (125), Thirty-four percent ofTCCs has LOH at one 
or more loci on chromosome 11 p or 11 q. A common region of deletion was defined at 11 p15, 
which is coincident with a region deleted in breast (3, 109), testicular cancers (107), and 
NSCCL (201), The target of these deletions is not known at present. A candidate gene is 
TSGI01, a suppressor gene identified by homozygous gene knockout through antisense 
RNA produced by a randomly introduced promotor (103), but this gene has not yet been 
shown to be mutated in human cancers. 
The role of chromosome 9 in bladder cancer 
LOH of markers on chromosome 9 is present in more than 50% of bladder tumors of all 
grades and stages and thereby is the most frequent genetic change identified (16, 17), 
These deletions are present at similar frequency in bladder tumors of all grades and stages 
and therefore represent a potential initiating event (176). In many tumors the region lost 
seems very large or involves regions on both chromosomal arms. This renders fine deletion 
mapping difficult. Several groups worldwide have studied large numbers of bladder tumors in 
order to identify small subchromosomal deletions that allow localization of the critical regions. 
Keen and Knowles (82) found a common region of deletion on 9p between D9S126 (9p21) 
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and the interferon-alpha cluster (IFNA) located also at 9p21. A single tumor showed a 
second site of deletion on 9p telomeric to IFNA, indicating the possible existence of 2 target 
genes on 9p. All deletions of 9q were large, with a common region of deletion between 
09S15 (9q13-q21.1) and 09S60 (9q33-q34.1). The results suggested the simultaneous 
involvement of distinct suppressor loci on 9p and 9q in bladder carcinoma. 
Refinement of the localization of loci on chromosome 9q has been described in a 
series of publications (16, 17, 36, 60, 64, 82, 186). This process is illustrated in Figure 5. 
First, the interpretation of the LOH data was based on the assumption that there was a single 
region of deletion on the chromosome or one on each chromosome arm (17, 82). LOH 
analysis of 9q based on larger numbers of markers suggested at least two regions at 9q13-
22 and 9q34 (60, 160). At 9q22, Simoneau et a/. (160), have examined the Gorlin syndrome 
gene (PTCH) and found no mutations. At 9q34, the TSCt gene was considered a candidate 
bladder tumor suppressor gene. Hamartomas developing in tuberous sclerosis patients with 
linkage to 9q34 show 9q34 LOH, indicating that TSCt may act as a tumor suppressor (184). 
SSCP analysis and sequencing have identified several mutations in bladder tumors with LOH 
in the region. This indicates that TSCt is a possible target of 9q34 deletions in a low 
percentage of bladder tumors (71, 127, 185). 
~ D9S18 
Caimset 
;:!I., 1993 
Keen and 
Knowles, 1994 
Devlin ot 
al.,1994 
ID9S153 095109 
109561 09566 
Habuchi ot 
al.,1995 
ID9S165 095176 
1095275 
0951826 
vanT[lboTg 
ohl.,1999 
Habuchi et 
aJ., 1997 
~'CDKN2 
Candidate 
gonos 1999 
Figure 5. Sequential refinement of LOH regions on chromosome 9 in bladder cancer. The regions are indicated by 
black lines next to the chromosome, together with the markers determining the borders. Adapted from Knowles, 
1999 (87). 
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A third possible tumor suppressor harbouring region was localized to 9q32-33, based on the 
finding of five tumors with small interstitial deletions in the region of D9S195 (127). A 
homozygous deletion was found in a region covered by a single YAC, whose estimated size 
was about 840 kilobase (64). This region was found to contain the cDNA sequence of the 
gene DBCCRt (for. deleted in bladder cancer chromosome reg'lon candidate 1) (61). The 
DBCCR1 cDNA sequence contains an open reading frame with 8 exons encoding a protein 
of 761 amino acids with an estimated molecular weight of 89 kD. Mutation analysis of the 
coding region in the five critical tumors and a series of tumors with larger deletions of 9q by 
SSCP analysis and Southern blot analysis detected neither somatic mutations nor gross 
genetic alterations in primary TCCs of the bladder. DBCCRt is expressed in multiple normal 
human tissues including urothelium, but mRNA expression is absent in 5 of 10 bladder 
cancer cells lines. Methylation analysis of the CpG island at the 5' region of the gene and the 
induction of de novo expression by a demethylating agent indicated that this island might be 
subject to hypermethylation-based silenCing. 
Outline of this thesis 
The identification of the genetic alterations in transitional cell carcinoma of the bladder could 
clarify the pathogenesis of this disease, provide insight into the possible presence of different 
genetic backgrounds, and eventually result in useful clinical tools. Genetic alterations on 
chromosome 9 are considered pivotal to bladder tumor development since deletions of this 
chromosome are present at high frequency in bladder tumors of all grades and stages. We 
first screened bladder tumors with several techniques that can detect loss of chromosome 9 
in order to effectively select out those tumors that have lost an entire copy of this 
chromosome (Chapter 2). From this work we concluded that LOH analysis is to be preferred 
over ISH in order to reliably determine loss of chromosomes. We further searched for 
common regions of deletion with LOH analysis and homozygous deletion mapping in order to 
narrow down the candidate regions (Chapter 3). We subsequently selected several known 
genes in the regions of loss to screen for mutations and susceptibility polymorph isms 
(Chapter 4). When it became clear that there were several regions of LOH on chromosome 9 
but very few mutations in any of the candidate genes, we started questioning the relevance 
of the regions. We therefore decided to search for common alterations in multiple superficial 
recurrent tumors in order to reconstruct the development of the genetic aberrations in time. 
This allowed us to order the tumors in a genetic tree, where tumors with few aberrations 
precede those with many. Based on the extent of the genetic damage and the accumulation 
of alterations during tumor development we hypothesize that LOH is presumably stimulated 
by an enhanced rate of mitotic recombination (Chapter 5). The genetic trees also allowed us 
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to interpret the LOH results on chromosome 9q and follow the development of as many as 
ten different events in tumors of individual patients. Since loss on chromosome 9q was 
almost never the characteristic first step in our patients and the regions lost varied between 
patients, we believe that this diminishes the probability of the presence of postulated 
gatekeeper genes on this chromosomal arm (Chapter 6). 
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Chromosome 9 copy number changes 
Summary 
The most frequent genetic aberration found in transitional cell carcinoma (TCC) of the 
bladder involves chromosome 9. Loss of heterozygosity (LOH) analyses show deletions of 
both chromosome 9p and 9q, while in situ hybridization studies suggest a significant 
percentage of tumors with monosomy 9. To investigate the types of chromosome 9 losses 
that occur in bladder cancer, we studied forty tumors with different techniques such as in situ 
hybridization (ISH), flow cytometry and LOH analysis. 
LOH for one or more markers was found in 43% of the tumors. This percentage does 
not differ from previous reports. With ISH, complete monosomy for chromosome 9 was 
observed in only 1 of the 40 tumors. Four other tumors had monosomic sub populations, 
representing 23-40% of the cells. In 18 cases an underrepresentation of the chromosome 9 
centromere relative to chromosome 6 or to the ploidy of the tumor was observed, these 
include the cases with monosomy. In 5 of these 18 cases the relative loss could not be 
corroborated by LOH. In addition, when LOH and a relative underrepresentation were 
observed in the same tumor, the extent of LOH as measured by the intensity of allele loss 
was often not related to the extent of underrepresentation. We therefore conclude that 
complete monosomy of chromosome 9 is rare in TCCs of the bladder and that a relative loss 
of centromere signal may not be related to loss that is meant to inactivate a tumor 
suppressor gene. LOH was found in TCCs of all stages and grades. This suggests that loss 
of tumor suppressor genes on chromosome 9 is an early event in the pathogenesis of 
bladder cancer. 
Introduction 
Transitional cell carcinoma (TCC), the most common form of urinary bladder cancer, is 
presented in two ways: superficial papillary tumors (Tarn) and invasive tumors (T2-T4). 
Other types of bladder tumors include carcinoma in situ (CIS), squamous cell carcinomas 
and adenocarcinomas. Aberrations concerning chromosome 9 are found in TCCs of all 
grades and stages, suggesting that the inactivation of a tumor suppressor gene (TSG) on 
this chromosome is an early event in the development of bladder cancer. Loss of 
heterozygosity stUdies show loss of heterozygosity (LOH) on both chromosome arms in more 
than 50% of the tumors (60, 88). Fluorescent in situ hybridization (FISH) analyses show that 
the number of chromosome 9 centro meres is often lower when compared to other 
chromosomes (149, 202). Thus, chromosome 9 is relatively under-represented. In addition, 
subpopulations of tumor nuclei are found in which only one spot for the centromere 9 probe 
is observed, which suggests monosomy for chromosome 9 in at least a part of the tumor 
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cells. Finally, with comparative genomic hybridization (CGH) loss of chromosome 9 is 
observed in about 25% of the TCCs (78, 196). A combination of LOH, FISH and CGH results 
led to the interpretation that monosomy of chromosome 9 may occur in over 50% of the 
TCCs of the bladder. 
Besides possible loss of entire copies of chromosome 9, interstitial deletions have 
been observed on both chromosome arms (82). This suggests that at least two and perhaps 
even three TSGs on this chromosome may contribute towards the development of bladder 
cancer. The TSG on chromosome 9p is generally believed to be the CDKN2A (MTS1, p16) 
gene and in many cases even homozygous deletions within this gene have been found (13, 
127). On the q arm, two shortest regions of loss have been determined (60, 186). These two 
regions are still too large to start cloning of the putative TSGs by positional cloning. In order 
to narrow down these regions we wanted to screen Tees for LOH and, in addition, to search 
for homozygous deletions. For determining a shortest region of loss by LOH analyses tumors 
with monosomy for chromosome 9 are not useful. On the other hand, these tumors can be 
used to search for homozygous deletions. We therefore decided to screen our tumors first by 
;n sUu hybridization and use the results to determine whether the sample would be used for 
LOH or homozygous deletion analysis. To our surprise, monosomy for chromosome 9 was 
observed in only 1 of the 40 tumors. 
To further evaluate the types of chromosome 9 losses that could inactivate tumor 
suppressor genes in TCCs of the bladder, we also determined the DNA-index and searched 
for LOH of chromosome 9 in tumor DNA. From the data obtained it appeared that a relative 
underrepresentation of chromosome 9 and LOH are often present in the same tumor. 
However, a quantitative interpretation of these data suggests that a relative 
underrepresentation and LOH are not causally related. Therefore, we conclude that complete 
monosomy of chromosome 9 is rare in these tumors and that a relative loss of centromere 
signal may not be related to loss that is meant to inactivate a tumor suppressor gene. 
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Materials & Methods 
Flow cytometry and in situ hybridization 
Forty paraffin-embedded archival bladder tumors were examined microscopically by a 
pathologist (T. v/d K.), and the parts which represented tumor tissue were punched out of the 
original paraffin blocks and newly embedded. Necrotic and/or inflammatory parts were 
avoided. An H&E stained section was made before and after every tissue handling, to ensure 
the comparability of the samples. These sections were again valuated by a pathologist. The 
percentage of tumor cells in the new blocks was estimated to be at least 90%. For flow 
cytometry, cell suspensions were made according to the method of Hedley (68). After 
deparaffinization, cells were resuspended in Hank's BBS with ethidium bromide (50 ~g/ml), 
treated with RNase and filtered (40 ~m). Samples were counted on a FACScan (Becton 
Dickinson Co, Sunnyvale, CAl. A total of 10,000 nuclei were analyzed for each sample. 
Peaks were only considered significant when they comprised more than 20% of gated 
events. The DNA-index was determined as the ratio of the aneuploid mean channel number 
divided by the diploid mean channel number. 
For in situ hybridization, interphase nuclei were isolated from 20 J,Jm sections of the 
new blocks. Sections were deparaffinized and digested with 0.1 % subtilisin (Sigma protease 
XXIV) at 3JOC in 0.1 M Tris, 0.07 M NaCI, pH 7.2, for 25-40 min. Suspensions were filtered 
(40 J,Jm). The nuclei were spin ned onto slides. Centromere associated probes for 
chromosome 9 (pHUR98) (120), and, as a control, chromosome 6 (p308) (75), were used. 
Probes were labeled by nick-translation with biotinylated dNTPs. DNA probes were stored at 
-20·C. The ISH procedure was performed as described by Van Dekken ef al. (181). Briefly, 
the slides were subjected to a microwave treatment of 10 min at 85·C in 2xSSC, followed by 
a 0.1% pepsin digestion. Nuclear DNA was denatured in 70% formamide/2xSSC, pH=7.0 at 
70'C for 2 min, followed by dehydration in ethanol. The hybridization mixture was denatured 
for 5 min at 70'C. Hybridization was performed overnight at 3JOC in a humidified chamber. 
Visualization was done with diaminobenzidin (DAB). The CARD technique (CAtalyzed 
Reporter Deposition) (83), was used to amplify the Signal for chromosome 9. The distribution 
of centromeric signals was determined by counting 200 nuclei per tumor per probe. All intact 
nuclei were included in the analysis. A tumor was considered disomic if no other sub-
population had >20% of tumor cells. A tumor was considered to have a monosomic sub-
population of cells when this sub-population comprised more than 20% of the cells. When the 
monosomic population was the largest population of cells in a tumor, representing over 70% 
of the cells, this was interpreted as a complete monosomy for chromosome 9. 
Underrepresentation of chromosome 9 was considered when the average number of spots 
for chromosome 9 differed more than 0.3 from the average number of spots for chromosome 
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6 and/or the tumor had a considerable sub-population of tetra-/aneuploid cells as determined 
with FCM while the number of spots for chromosome 9 was lower than the ploidy would 
predict. 
DNA preparation and LOH analysis 
Matched pairs of bladder tumors and normal control tissue of the same patient was isolated 
by proteinase K (2 mg/ml) digestion of deparaffinized 5 ~m sections, followed by 
phenol/chloroform extraction and ethanol precipitation. For LOH analysis, microsatellite 
primer sequences were obtained from the Genome Data Base (http://gdbwww.gdb.org/gdb). 
The following primers where included: D9S178, D9S168, D9S156, D9S171, D9S165, all 
located on chromosome 9p, and D9S166, D9S153, D9S264, D9S283, D9S197, D9S196, 
D9S280, D9S180, D9S272, D9S173, D9S154, D9S275, D9S195, D9S179, D9S164, 
D9S158, all located on chromosome 9q. Primers are listed in linkage order. Template DNA 
(±50 ng) was amplified in a total volume of 15 ~I reaction mixture containing 2.5 ~M dNTPs, 
10 pmol of the appropriate primer combination, and 0.25 units of Taq polymerase (Promega). 
Products were labeled with a-"P-dATP. Thermal cycling consisted of initial denaturation at 
95°C for 5 min, followed by 30 cycles of each 55°C for 45 sec, 72°C for 45 sec, and 94°C for 
45 sec. The final elongation step was 72°C for 10 min. PCR-products were separated on 6% 
denaturing polyacrylamide gels. Detection was done by autoradiography and, when 
necessary, followed by quantification using a Phosphorlmager (Molecular Dynamics, 
Sunnyvale, CAl. An allele was considered to be lost when the intenSity of the remaining 
signal was less than 50% compared to the signal of the same allele in the matching control 
DNA of the same patient. However, the intensity of the lost alle[e in most tumors was 30% or 
less. 
Statistical analysis 
The Chi-square test was used to determine the correlation between tumor stage and grade, 
loss of chromosome 9 as detected with polymorphic markers or in situ hybridization, and 
DNA-index. A p-value of <0.05 was considered significant. 
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Results 
DNA analyses 
In order to obtain a better insight in the loss of chromosome 9 sequences in TCCs of the 
bladder and the possible mechanisms by which these losses occur, we investigated forty 
TCCs with different techniques. The combined results are depicted in Table 1. The grade 
and stage of the tumors is included in the table. Loss of heterozygosity (LOH) was 
detenmined by PCR with primers for several microsatellite markers for both the p and q arm 
of chromosome 9. In Table 1, LOH is indicated by Y(es) or N(o), and the number of 
microsateJlites that were examined for a given tumor is indicated between brackets. Flow 
cy10metry was used to determine the DNA-ploidy of the tumor. 
The results are shown in Table 1 as the DNA-index, i.e. the ratio between the 
distance of a possible aneuploid peak and the peak representing the diploid nuclei. In 
addition, the percentage of nuclei in the diploid (peak 1) and aneuploid (peak 2) peaks is 
given to reflect the relative number of tumor cells within each subpopulation. In situ 
hybridization (ISH) was performed with probes for centromeres of chromosomes 6 and 9. In 
Table 1 the results obtained are represented by the average number of spots for each probe 
per nucleus. In order to facilitate the interpretation, Table 1 is divided into tumors with an 
underrepresentation of chromosome 9 centro meres relative to either the number of spots for 
chromosome 6 and/or the DNA-ploidy (Table 1A) and those with LOH but without any 
indication for numerical aberrations of chromosome 9 (Table 18) and finally, Table 1 C 
represents those cases in which no indication for numerical or structural aberrations were 
obtained. The complete in situ hybridization data for the tumors from Table 1A and 8 are 
shown separately in Figure 1. 
In 5 tumors (tcc5, 8, 20, 36, and 57), monosomy for chromosome 9 was observed in 
more than 20% of cells. The ISH countings of these tumors are shown in Figure 1. Tumor 57 
is the only example with monosomy in the largest population of cells: over 70% of the nucle'l 
have one spot for the centromere 9 probe. Figure 2 shows representative areas of the slides 
with interphase nuclei of this tumor hybridized with a probe for chromosome 6 (Figure 2A) 
and chromosome 9 (Figure 28). This result is corroborated by the LOH analysis in which a 
clear loss of all but one microsatellite marker was observed, 
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Table 1. Histopathological stage and grade. chromosome 9 loss and 
DNA-index in transitional ceff carcinoma of the bladder 
Pathology LOH ISH 
-----"'--------- "::::.:.'----------- average # of spots 
FLOW CYTOMETRY 
peak1 peak2 DI 
TCC T G 9p 9q chromo 6 chromo 9 % 
A) tumors with an underrepresentation of chromosome 9 centromeres 
5 3 3 Y(1) Y(4) 2.46 
6 4 3 N(1) Y(1) 2.50 
8 
14 
16 
18 
20 
25 
26 
34 
35 
36 
37 
40 
42 
43 
44 
57 
61 
1 
3 
3 
3 
CIS? 3 
2 3 
1 3 
2 3 
2 3 
2 3 
2 2 
2 
2 3 
a? ? 
2 3 
1 3 
2 3 
1 2 
2 3 
nd 
N(1) 
nd 
Y(2) 
nd 
N(1) 
nd 
nd 
Y(1) 
N(1) 
nd 
Y(1) 
Y(1) 
nd 
Y(2)/N(1) 
Y(1) 
nd 
nd 
N(3)/Y(1) 
N(1)/y(2) 
Y(4)/N(2) 
N(2) 
N(6) 
N(1) 
nd 
Y(3) 
Y(3)/N(14) 
N(3) 
Y(5) 
Y(3)/N(2) 
N(4) 
Y(6)/N(1) 
Y(10)/N(1) 
nd 
2.38 
2.55 
1.80 
3.25 
2.21 
2.64 
2.20 
3.89 
2.43 
2.20 
3.35 
2.42 
3.19 
3.33 
3.02 
1.92 
4.19 
B) tumors with LOH and no underrepresentaflon of chromosome 9 
3 a 1 nd Y(1) 1.87 
12 3 Y(1) Y(4) 2.02 
22 a 2 N(5) Y(7) 1.89 
39 a 2 N(3) N(2)/y(7) 3.36 
60 a 2 Y(1) Y(6)/N(2) 2.00 
C) tumors without indication for loss of chromosome 9 
2 ? 2 N(1) N(3) 
4 2 3 N(2) nd 
7 a 1 N(1) N(4) 
10 3 N(1) N(1) 
29 1 2 N(2) N(4) 
33 2 3 nd N(6) 
38 2 3 N(2) N(10) 
46 ? 3 N(1) N(4) 
49 1 2 N(1) N(7) 
50 2 3 nd N(2) 
53 ?? N(1) N(9) 
54 a 2 N(1) N(9) 
56 2 3 nd N(4) 
58 a 1 N(1) N(8) 
59 a 1 nd N(9) 
62 2 3 nd N(1) 
38 
1.95 
2.76 
2.11 
3.31 
1.93 
2.00 
2.28 
3.44 
3.60 
3.43 
2.01 
1.96 
1.99 
2.01 
1.88 
2.17 
1.99 
2.21 
1.70 
2.74 
1.88 
2.00 
2.07 
2.23 
2.22 
2.76 
2.01 
1.59 
2.93 
2.37 
2.74 
2.36 
2.89 
1.26 
3.61 
1.88 
2.06 
1.91 
3.16 
1.99 
1.93 
2.75 
2.04 
3.19 
1.88 
1.97 
2.30 
3.52 
3.53 
3.38 
1.96 
1.99 
1.99 
1.91 
1.84 
2.16 
59 
64 
64 
16 
29 
46 
31 
64 
39 
20 
37 
65 
19 
40 
47 
49 
26 
53 
23 
nd 
nd 
59 
47 
57 
65 
57 
44 
nd 
22 
62 
22 
19 
57 
24 
69 
58 
42 
68 
46 
49 
% 
6 
11 
3 
49 
23 
21 
20 
6 
24 
28 
32 
7 
35 
34 
9 
9 
9 
8 
31 
nd 
nd 
8 
20 
7 
4 
10 
8 
nd 
21 
9 
35 
35 
9 
26 
1 
7 
7 
4 
8 
6 
1.00 
1.00 
1.00 
2.00 
1.98 
1.87 
1.98 
1.00 
2.00 
2.34 
1.90 
1.00 
1.70 
2.10 
1.00 
1.00 
1.00 
1.00 
2.90 
nd 
nd 
1.00 
2.00 
1.00 
1.00 
1.00 
1.00 
nd 
1.10 
1.00 
1.60 
1.80 
1.00 
2.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
Chromosome 9 copy number changes 
Tcc8 and 36 apparently are heterogeneous and have a subpopulation of monosomic tumors 
cells, reflected by the 40% nuclei with one spot for chromosome 9. Tcc36 is a special case in 
which the 40% monosomic sub-population is accurately reflected by a lower signal for 7 LOH 
markers (about 60-70% signal remaining). This is not reported as LOH in the table because 
the percentage signal that is left, is higher than the definition we use for LOH. In addition, this 
tumor harbours an interstitial deletion on one chromosome 9, which results in 3 markers with 
about 30% remaining signal (the markers with LOH in the table). Unfortunately no DNA was 
available for LOH analysis of tceB. In tceS and tcc20 only a small fraction of the cells 
appeared to have lost one copy of centromere 9. However, for tcc5 the LOH on both p and q 
arms as judged from the relative intensity of the auto radiographic signals is much higher than 
can be explained by the percentage of cells with monosomy (results not shown). In tcc20 no 
LOH was observed. A discrepancy between loss of chromosome 9 centromere spots relative 
to chromosome 6 andlor the ploidy on the one hand and the extent of loss in the LOH 
analyses on the other was observed for tcc5, 6, 14, 16, 18,20,25,26,35, 37, 42, and 43. 
Taken together, this means that a concordance between the LOH results and the ISHlflow 
cy10metry was obvious in 3/18 cases (tcc36, 40 and 57), and no concordance was observed 
in 12/18 cases. In 3118 cases no LOH data were obtained due to insufficient tumor material. 
Statistical correlations between parameters 
No correlation could be found between chromosome 9 loss as detected with LOH and tumor 
stage or grade. The chromosome 6 probe correlated well with the DNA-index (p=0.024). 
Although an association was found between chromosome 9 underrepresentation as detected 
with in situ hybridization and LOH (p=0.0063), this is misleading, since the extent of loss in 
the LOH analyses is much higher than can be explained by the extent of underrepresentation 
of chromosome 9. 
Figure 1. (next page) Distdbution of centromere 6 and 9 signals as determined by in situ hybddization of the 
tumors with LOH or underrepresentation of chromosome 9. ShOwn are the number of spots for chromosome 6 
and 9 per nucleus in 200 nuclei per tumor. On the X~axis are the number of spots, varying betNeen no spots (0) 
and 5 or more spots (>5). On the Y~axis are the number of nuclei. The results for chromosome 6 are represented 
by light bars, the results of chromosome 9 by dark bars. Only tcc5, 8, 20, 36 and 57 have a significant population 
of cells with monosomy 9. 
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Figure 2, DNA-ISH on isolated interphase nuclei of bladder tumor 57. Biotinylated probes were visualized with 
DAB. (AJ With probe p308, specific for the centromeric region of chromosome 6, two spots are visible per 
nucleus. (8) Monosomy 9 is detected after hybridization with the centromere 9 associated probe pHuR98, 
Discussion 
In our series of Tees, 18 tumors displayed a relative loss of the chromosome 9 centromere 
when compared with chromosome 6 or the ploidy. In 5 of these, no loss was observed in the 
LOH analysis. This suggests that in these cases the relative under-representations had 
nothing to do with monosomy 9 as a way of inactivating a tumor suppressor gene. In the 
cases where LOH was detected, the extent of loss did not correlate with the relative 
numerical [ass observed with ISH and flow cytometry in 12/18 cases. Moreover, in 7110 
samples with an underrepresentation of chromosome 9 and LOH the loss was regional and 
did not cover the entire chromosome. Again this suggests that relative loss and LOH are two 
different entities and that the relative loss is not instrumental in bringing about LOH. 
Aberrations concerning chromosome 9 have been observed by several investigators 
using techniques such as LOH analysis, F[SH and CGH. However, there are some important 
differences between the techniques and this affects the significance of the obtained results 
with respect to the interpretation of tumor pathogenesis. When LOH is scored, in general this 
will imply that the intensity of the lost alle[e is visually much [ower than that of the control. 
Thus, the loss is relatively clear-cut and it can safely be concluded that the region in which 
the marker(s) is located has been deleted in most of the tumor cells. The remaining signal 
can convincingly be explained by the presence of a percentage of non-tumorous endothelial 
or stromal cells in the tissue block. This is much less the case when loss is studied using 
FISH. Using this technique, most authors conclude that loss of chromosome 9 has occurred 
when a relative underrepresentation of chromosome 9 is observed when compared with the 
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number of spots for other chromosomes. A relative underrepresentation will also lead to an 
observed loss in the CGH analysis. In addition, when monosomy of the chromosome 9 
centromere is observed with FISH, this loss is frequently only observed in a subpopulation of 
nuclei (70, 135, 149). This picture clearly differs from other tumors in which monosomy for a 
chromosome is observed. For instance, in about 60% of the meningiomas monosomy for 
chromosome 22 is found in over 80% of the analyzed cells (100). Thus, in TCCs of the 
bladder, pure monosomy present in almost all cells is rather rare. In our series of tumors the 
degree of relative loss of chromosome copies and the degree of LOH differed in the majority 
of tumors. Although an association was found between chromosome 9 underrepresentation 
and LOH, the extent of loss in the LOH analyses is much higher than can be explained by 
the extent of underrepresentation. We therefore conclude that there is no causal relationship 
between underrepresentation and LOH and that the observed correlation is spurious. 
As implicated above, the best evidence for involvement of chromosome 9 associated 
tumor suppressor genes in pathogenesis of transitional cell carcinoma of the bladder is 
obtained by LOH analyses. We observed LOH in 16/37 tumors, this means that in at least 
16/37 tumors (43%) of the TCCs putative tumor suppressor genes on chromosome 9 may 
playa role in pathogenesis. One tumor suppressor gene identified on 9p is the CDKN2A 
(p16, MTS1) gene. Cairns (13), showed that in 71% of primary bladder tumors homozygous 
deletions targeting this gene were detected. Besides the CDKN2A gene on 9p there is 
evidence for at least two other loci on chromosome 9q (60, 186). 
In Table 1, 5 tumors (tcc3, 5,12,35, and 40) have LOH for all tested markers. These 
tumors have 2 centromere 9 signals per nucleus. A possible mechanism by which this 
situation has occurred, is that first one copy of chromosome 9 was lost, for instance by non-
disjunction, later followed by reduplication of the preserved copy in the case of the diploid 
tumors or by tetraploidization in tcc35 and tcc40. Alternatively, the LOH is due to interstitial 
deletions on both arms with retention of the centromere. In tcc16, 18, 22, 39, 57 and 60 not 
all markers show LOH. Tumor 57 is monosomic with respect to centromere 9 and tumor 39 
has an interstitial deletion on 9q (186). For the other 4 cases the regional losses may have 
occurred by interstitial deletions or by translocations. These tumors have 2 signals for 
centromere 9. The best explanation therefore is that the two centromere signals represent 
the two different copies of chromosome 9 and that the LOH is due to structural rather than 
numerical aberrations. A reduplication of the unaltered chromosome would be evident from 
the relative intensities of the microsatellite signals in the regions without LOH. These would 
differ from the allele intensities found in normal control DNA of the same patient and this was 
not found (results not shown). 
To check whether the tumors discussed in this article are a representative selection 
of transitional cell carcinomas of the bladder, we also determined their pathological 
42 
Chromosome 9 copy number changes 
parameters. From the 40 TCCs 18 were Tarn and 17 T2-T4, 4 were grade 1, 10 grade 2 
and 24 grade 3. These numbers do not differ Significantly from those found by other 
investigators. In addition, it appeared that the chromosome 6 copy number is related to the 
ploidy of the tumors, suggesting that the chromosome 6 centromere probe can reliably be 
used to reftect the ploidy of the tumors. No significant relations were observed between LOH 
perse, LOH for 9p or 9q, and tumor grade, stage or DNA-index. Also this finding is in 
agreement with other investigators (16). This suggests that the putative tumor suppressor 
genes on chromosome 9 that are the target of the LOH events most probably are involved in 
the early stages of the pathogenesis of these tumors. 
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Candidate tumor suppressor loci 
Summary 
The most frequent genetic alterations in transitional cell carcinoma (TCC) of the bladder 
involve loss of heterozygosity (LOH) on chromosome 9p and 9q. The LOH on chromosome 
9p most likely targets the CDKN2 locus, which is inactivated in about 50% of TCCs. 
Candidate genes that are the target for LOH on chromosome 9q have yet to be identified. To 
narrow the localisation of one or more putative tumor suppressor genes on this chromosome 
that playa role in TCC of the bladder, we examined 59 tumors with a panel of microsatellite 
markers along the chromosome. LOH was observed in 26 (44%) tumors. We present 
evidence for two different loci on the long arm of chromosome 9 where potential tumor 
suppressor genes are expected. These loci are delineated by interstitial deletions in two 
bladder tumors. Our results confirm the results of others and contribute to a further reduction 
of the size of these regions, which we called TCC1 and TCC2. These regions were examined 
for homozygous deletions with EST and STS markers. No homozygous deletions were 
observed in 17 different bladder tumor cell lines. 
Introduction 
Bladder cancer is the fifth most common cancer in males. Over 95% of all bladder cancers in 
industrialised countries are transitional cell carcinomas (TeCs). TCCs are presented in two 
ways: superficial papillary tumors, confined to the mucosa and lamina propria, and invasive 
tumors spreading beyond the lamina propria into detrusor muscle. The remaining 5% of 
tumors include squamous cell carcinomas, adenocarcinomas, and carcinoma in situ (CIS). 
Frequent somatic allelic loss is regarded as a hallmark of tumor suppressor gene 
(TSG) inactivation. In TCCs, cytogenetic studies and loss of heterozygosity (LOH) analyses 
have revealed a number of chromosomal aberrations, including deletion of chromosome 9p 
and/or 9q (16, 36, 82, 105, 129), and deletions of chromosome 11p (157), 18q (12), 
chromosome 8 (89, 170), 4p (39,136), and 14q (22). Loss of heterozygosity of markers on 
chromosome 9 is found in TCCs of all grades and stages, suggesting that the inactivation of 
a putative tumor suppressor gene (TSG) on this chromosome is an early event in the 
development of bladder cancer. Several groups (60, 144, 160), reported evidence for the 
presence of more than one TSG that can contribute to the development of bladder cancer on 
chromosome 9. The CDKN2A (p16, MTS1) and CDKN28 (P15) genes are localised on the 
short arm of chromosome 9. Recent studies showed the inactivation of these genes in as 
much as 40-50% of bladder tumors (2, 13). More detailed deletion mapping on the long arm 
revealed two regions of loss (60,160). Small interstitial deletions covering the location of the 
marker D9S195 were recently reported in 5 TCCs. The shortest region of overlap of these 
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deletions is estimated to amount to about 840 kb. The putative TSG in this Oeleted in 
Bladder Cancer region (OBC1) was called OBCCR1 (61). This OBC1 region does not overlap 
with the two other regions described by Habuchi and Simoneau et a/. Thus, the combined 
data provides evidence for 3 TSGs on chromosome 9q that may play a role in the 
pathogenesis of bladder cancer. 
In the present study we used a PCR-based microsatellite assay to further delineate 
the extent of the deletions at chromosome 9q. A combination of our data with those of others, 
supports the view that apart from the OBC1 region two other putative TSG loci may exist on 
chromosome 9q. These two regions were called TCC1 and TCC2. We screened 17 bladder 
tumor cell lines for homozygous deletions in these areas. No evidence for homozygous 
deletions was obtained. 
Materials and Methods 
DNA preparation 
Matched pairs of 59 paraffin-embedded bladder tumors and normal control tissue of the 
same patient were selected. Paraffin sections were examined microscopically by a 
pathologist (Th. v/d K). Parts that represented tumor tissue were punched out of the original 
paraffin blocks and newly embedded. ONA was isolated by proteinase K (2 mg/ml) digestion 
of deparaffinised 5 ~m sections, followed by phenol/chloroform extraction and ethanol 
preCipitation. A haematoxylin/eosin staining of sections flanking the sections used for DNA 
isolation was again controlled by the pathologist. In general the percentage tumor tissue in 
the material dissected by this procedure was estimated to be over 90%. 
The following bladder tumor cell lines were used: 253J, 575A, 647V, 1207, 5637, J82, 
Jon, RT4, RT112, SCaBER, SO, SW780, SW800, SW1710, T24, VMCubl, and VMCubl1. Or. 
O. Chopin, Paris, kindly provided the cell lines 1207 and 647V. Genomic ONA was prepared 
according to standard procedures (145). 
LOH analysis 
For LOH analysis, microsatellite primer sequences were obtained from the Genome 
DataBase (http://gdbwww.gdb.org/gdb).Thirty primer pairs were used. On the short arm, the 
markers 09S178, 09S171, 09S168, 09S165, and 09S156 were included. On the long arm, 
the markers 09S153, 09S154, 09S158, 09S164, 09S166, 09S173, 09S176, 09S177, 
09S179, 09S180, 09S195, 09S196, 09S197, 09S257, 09S264, 09S272, 09S275, 
09S278, 09S280, 09S283, 09S287, 09S1783, 09S1818, 09S1826, 09S1838 were used. 
Template DNA (50 ng) was amplified in a total volume of 15 ~I reaction mixture containing 
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2.5 mM dNTPs, 10 pmol of the appropriate primer combination, and 0.25 units of Taq 
polymerase (Supertaq). Products were labelled with a_32P_dATP. 
Thermal cycling consisted of initial denaturation at 95°C for 5 min, followed by 32 
cycles of each 55°C for 45 sec, 72°C for 40 sec, and 94°C for 40 sec. The final elongation 
step was 72°C for 10 min. PCR-products were separated on 6% denaturing polyacrylamide 
gels. Detection was done by autoradiography and, when necessary, followed by 
quantification using a Phosphorimager (Molecular Dynamics, Sunnyvale, CAl. An allele was 
considered to be lost when the intenSity of the remaining signal was less than 50% compared 
to the signal of the same allele in the matching control DNA of the same patient. 
HD screening 
For the homozygous deletion mapping, 98 primer sequences were obtained from the 
Whitehead Institute (http://www-genome.wLmit.edu/), the Sanger Centre 
(http://www.sanger.ac.uk). and The Institute of Genome Research (TIGR) 
(http://www.tigr.org). All primer sequences were from sequence tagged sites (STS) or 
expressed sequence tags (EST) mapped between our TCC1 and TCC2 border markers 
(http://www.ncbi.nlm.nih.gov/Science96). Amplification was done as described for the LOH 
analysis, with the exception of the presence of a second control primer set in the reaction 
mixture. As a control, primers were used for the NF2 (exon 5 and 11, (76)) or MN1 genes on 
chromosome 22 (bp 5304-5421, forward: MN1-16, 5'- AGG TTG GTA CCT GCT TAG TG, 
reverse: MN1-13, 5'- GGG TTA ACA CTG GTA ACA TAC), since there are no data 
suggesting the involvement of either of these genes or the chromosome in bladder cancer. 
Since the presence of a homozygous deletion in the CDKN2A gene was known in 8 of the 17 
cell lines used, primers were included for a 167 bp product spanning an intron-exon 
boundary of the CDKN2A gene (123). The detection of these deletions waS used as a 
positive control. 
Results 
LOH analysis 
Fifty-nine bladder tumors were screened for LOH of markers on chromosome 9. Twenty-six 
tumors (44%) showed LOH for one or more markers. No microsatellite instability was seen. 
Of these, 2 tumors had a deletion confined to the p arm, in 10 the loss was confined to the q 
arm and in 12 cases both p and q arms were affected. Losses on the short arm overlap the 
region containing the CDKN2 locus, which is located telomeric to marker D9S171. Two 
individual tumors were found to obtain different interstitial deletions on chromosome 9q, 
suggesting two different TSG loci on this chromosome arm. These are discussed in detail in 
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the following sections. Other regions of loss that were observed on 9q could target both 
putative TSG loci on 9q and/or the CDKN2 locus and did not contribute to a further 
delineation of these loci. 
An interstitial deletion between 095165 and 095176 
In tcc39 an interstitial deletion was observed between the flanking markers D9S165 and 
D9S176. No loss was observed for 3 microsateliite markers on 9p. Examples of the LOH 
analysiS of 9q are shown in Figure 1A. Between D9S165 and D95176. a clear LOH was 
observed for 7 microsatellites. The autoradiogram for one of these, D9S283 is shown in 
Figure 1A. The extent of loss was also calculated with the Phosphorimager. The results 
obtained are depicted in Table 1 in the lane marked Tcc39. For D9S283 the signal of the lost 
allele was measured to be 13% of that of the control allele from normal tissue. For some of 
the other markers slightly higher values were observed. This is probably due to the fact that 
when two alleles are relatively close together and comprise several stutter bands, they 
contribute to each others background. In some cases, i.e. for D9S272 and D9S1783, this 
makes the quantitative analysis impossible, although with the eye a clear LOH is evident. 
The region deleted in tcc39 is approximately 48 cM in size. Tcc39 was classified by the 
pathologist as Ta/grade II. 
A B 
tcc39 tcc36 
N T N T N T N T N T N T 
., 
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.- ~-~~ 
• .-
D9S165 D9S283 D9S176 D9S275 D9S195 D9S1826 
Figure 1. Autoradiographs iflustrating the LOH analyses for tcc36 and tcc39. N: matched control DNA; T; tumor 
DNA. Arrows indicate deleted alleles. (AJ tcc39: markers 095165 and 095176 show retention, while marker 
D95283 shows loss of the lower allele. (8) tcc36: markers 09S275 and 0951826 show retention, while marker 
D9S195 shows a lower intensity of the upper allele. 
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An interstitial deletion between 095275 and 0951826 
Tcc36 is a Tl/grade II bladder tumor in which 40% of the cells are monosomic for 
chromosome 9 as determined by in situ hybridisation using the chromosome 9 
heterochromatin region probe pHUR98 (187). Thus tcc36 is heterogeneous with respect to 
its genomic constitution. This partial loss of one copy of chromosome 9 is also observed in 
the LOH analyses and is reflected by the measured intensities of allele signals of around 
60% as shown in Table 1. Three microsatellites show a remaining signal of approximately 
30-40% when compared to the control DNA. This most likely reflects an interstitial deletion of 
31 cM flanked by markers 095275 and 0951826. Figure 18 shows representative 
autoradiograms of the LOH analyses of tcc36. Based on the signal intensities as measured 
by the Phosphorimager, the most plausible model to explain these findings would be that one 
allele of a putative TSG which is located within the interstitially deleted area was first 
inactivated and that two individual second hits targeting the other allele occurred in separate 
cells: a) loss of an entire copy of chromosome 9 as reflected by the subpopulation of 40% of 
the tumor cells that are monosomic for chromosome 9 and b) an interstitial deletion of the 
same copy of chromosome 9 present in approximately 25% of the tumor cells. 
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Figure 2. The borders of the TCC1 region. Markers are shown in linkage and physical mapping order according to 
the Whitehead fnstitute contig data and CEPHIGEmethon data. White circles: retention; black circles: loss of 
heterozygosity: grey circles: not informative. On the right side, a vertical bar indicates the potential smallest region 
of overlap, based on our results with tcc39 and the results of Habuchi et al. (60). 
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Figure 3. The borders of the DBC1 and TCC2 regions. Markers are shown in linkage and physical mapping order 
according to the Whitehead Institute contig data and CEPH/GEmethon data. White circles: retention; black circles: 
ross of heterozygosity; grey circles: not informative. On the right side. vertical bars indicate the possible smallest 
regions of overlap, based on our results with tcc36 and the results of Habuchi et al. (60, 64). and Simoneau et al. 
(160). For an exp{anation of the 3 possible SROs for TCC2 (A, B, and C), see text. 
Table 1. Percentages of allele signal left for tcc36 and tcc39 
as determined with the Phosphon·mager. n 
Marker Tcc36 Tcc39 
D9S165 
D9S166 
D9S264 
09S283 
09S197 
D9S280 
09S287 
09S180 
09S272 
D9S1783 
09S176 
09S173 
D9S177 
D9S154 
09S275 
09S195 
09S179 
D9S164 
09S1818 
09S1826 
D9S158 
09S1838 
0.87 
0.51 
0.57 
0.59 
0.64 
0.73 
0.37 
0.38 
0.44 
N.r.b 
0.60 
0.86 
0.65 
0.94 
0.34 
0.15 
0.13 
0.19 
0.22 
N.M.c 
N.M. 
0.77 
0.89 
1.14 
0.76 
0.60 
"The percentages were determined by comparing the intensity of the lost allele in the tumor with the intensity of 
the same allele in normal control DNA, in relation to the intensity of the other retained allele. bN.I" Not Informative; 
"N.M., Not Measured. 
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Homozygous deletion analysis 
We next screened DNA from 17 bladder tumor cell lines for homozygous deletions in these 
areas. For the more centromeric region, 83 ESTs and STSs were selected between the 
markers D9S153 and D9S176, a region of 27 cM. The borders of this region are indicated in 
Figure 2, they were deduced based on our results with tcc39 and the results of Habuchi et a/. 
(60). The markers for the homozygous deletion analysis are listed in Table 2. When the 
markers are randomly distributed, this results in a density of one marker per 300 kb. SpeCial 
attention was paid to the prevention of contaminating the peR-reaction to avoid false 
positives, by strictly separating the equipment used to handle amplified DNA from other 
equipment. Separate work areas were used for pre- and post-amplification steps. Random 
negative controls were included. No homozygous deletions were found. In addition, the 
region with an interstitial deletion as defined by tcc36 was screened with 15 sets of PCR 
primers, representing a density of 1 marker per 500 kb. However, no evidence for 
homozygous deletions was obtained. As a control we also screened the cell lines for 
deletions of the CDKN2 locus. Deletions were observed in 8 of the 17 cell lines tested. This 
confirms data obtained by others (164, 171,204). 
Table 2. Overview of the £STs and STSs used for HD mappng, 
ordered from centromere to telomere. 
Located in TCC1 Located in TCC2 
1 stSG8675 22 A006N11 43 A002D08 64 WI-7285 84 U18543 
2 WI-30336 23 A006U15 44 A008R29 65 WI-11414 85 IB3089 
3 A002Y36 24 NIB973 45 IB543 66 AOO1T44 86 WI-13592 
4 WI-11585 25 stSG1471 46 WI-2958 67 WI-8684 87 WI-11542 
5 CKS2 26 stSG2118 47 WI-6937 68 TGFBR1 88 WI-6257 
6 WI-11909 27 NIB722 481R10 69 A008N47 89 WI-12734 
7 W!-16825 28 stSG2205 49 WJ-13546 70 A005N10 90 ROP 
8 WI-12646 29 stSG3724 50 PTCH 71 WI-7447 91 WI-11957 
9 stSG2370 30 WJ-7541 51 WJ-14826 72 WI-5249 92 FB23F1 
10 stSG8105 31 WI-13139 52 WI-1941 73 WI-14669 93 WI-15097 
11 WI-2414 32 A007K29 53 WJ-2013 74 WI-7344 94 WI-13608 
12 stSG9248 33 WI-6338 54 stSG9221 75 WI-3790 95 NIB1929 
13 WI4860 34 WI-6428 55 WI-9350 76 NIB1437 96 WI-14271 
14 A004T01 35 WI-4577 56 A006115 77 WI-15742 97 WI-11577 
15 IB2336 36 W!-532 57 WI-6378 78 WI-688 98 WI-12991 
16 183559 37 WI-8025 58 stSG8121 79 SGC31311 
17 WI-9447 38 stSG1737 59 WI-9840 80 WI-11370 
18 WI-2331 39 stSG2403 60 WI-9914 81 WI-2008 
19 WI-6758 40 WI-15517 61 WI-9212 82 A008T08 
20 WI-17567 41 AOO1U11 62 A003P31 83 WI-4017 
21 WI-9905 42 W!·2820 63 WI-7974 
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Discussion 
The purpose of this study was to further define chromosome 9q deletions in TCes. Previous 
LOH analyses predicted that 57% of tumors had deletions on chromosome 9p and 9q (60). 
The putative presence of two or more TSGs on the same chromosome complicates the 
interpretation of the LOH analysis. Most estimations for the losses of the whole chromosome 
are based on allelotyping studies in which a limited number of 9p and 9q markers were used. 
This causes high percentages of apparent complete loss of chromosome 9. It is our 
experience that when more markers are used most of these apparent cases of monosomy 
are in fact large terminal or interstitial deletions. This emphasises the importance of testing 
as many informative polymorphic markers as possible. The CDKN2A (p16)/CDKN2B (p15) 
tumor suppressor genes are located on the short arm of chromosome 9. Loss of one or even 
both copies of these genes was shown to occur in at least 40-50% of TCCs (2, 13). In some 
cases the region of LOH spreads from the CDKN2 region beyond the centromere into the q 
arm of chromosome 9. Such a deletion could target the CDKN2 region, a locus on the q arm 
or even both. In addition, losses that are confined to the q arm of chromosome 9 suggest the 
existence of more than one candidate bladder gene on this arm. Also here it is often not 
possible to define to which region the observed LOH contributes. 
Our LOH results confinm the hypothesis that there are at least two different putative 
tumor suppressor gene loci on the q arm. The first, more centromeric region is called TCC1. 
The borders of this new region, as depicted in Figure 2, are defined by the interstitial deletion 
in tcc39 as reported in this work and an interstitial deletion in a bladder tumor number 1 as 
published by Habuchi et a/. (60). For the definition of the region we have excluded tumors in 
which LOH was observed based on only one tested marker. Our results place the lower 
border of the TCC1 region at marker 09S176, instead of 09S109. This reduces the size of 
the region with 6 cM from 33 to 27 cM. In both our case tcc39 and case 1, the signal 
intensities of the remaining alleles are very low, suggesting that the gene targeted by these 
deletions is inactivated in most if not all tumor cells. Thus, inactivation of this gene may 
represent an early event in the pathogenesis of these tumors. 
For the definition of a second region, several possibilities exist. These are shown in 
Figure 3. In this figure the interstitial deletion in tcc36 (this paper) is shown next to deletions 
as published by the group of Knowles (60, 64). The OBC1 region was deducted from short 
interstitial deletions in 5 separate tumors that have a shortest region of overlap of 840 kb in 
which marker 09S195 is located (64). The first conclusion from these combined data is that it 
is impossible to attribute all deletions to one region. For instance, cases 36 and 1 can both 
target the OBC1 region, but case 2 clearly falls outside this region. The 3 different possible 
SRO regions based on these data are also shown in Figure 3. In A, it is assumed that both 
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tcc36 and tcc1 target the DBC1 region. This would result in a TCC2 region defined by case 
2. In option B, tcc36 targets DBC1 and tcc1 theTCC2 region and reversely in option C, the 
case 2 deletion targets DBC1 and tcc36 TCC2. As a result, the size of the TCC2 region can 
vary from 30 to 40 cM. 
Approximately 40% of the cells in tcc36 are monosomic for chromosome 9 and in an 
additional 25% an interstitial deletion of the same copy of chromosome 9 occurred. This 
suggests that both the interstitial deletion and the loss of an entire chromosome may target 
the same tumor suppressor gene and that for this gene these two events represent separate 
second hits. These findings suggest that the inactivation of the proposed TSG at this location 
may not have been one of the first hits in the pathogenesis of tcc36. 
Losses of chromosome 9q have also been observed in basal cell carcinoma (153), 
squamous cell carcinoma of the head and neck (1), oesophagus carcinoma (117), ovarian 
cancer (152), renal cell carcinoma (19), and small cell lung cancer (116). Since the SROs for 
bladder cancer are still very large, with the exception of the DBC1 region, it cannot be 
excluded that the losses seen in other tumors target the same TSGs. Recently, the gene 
responsible for sporadic basal cell carcinoma of the skin and the hereditary disorder NBCCS 
was identified. This PTCH gene is located within the TCC1 region. However, no mutations in 
this gene in bladder tumors were observed (160, our unpublished results). For oesophagus 
carcinoma, the region containing a putative tumor suppressor gene has been narrowed down 
to about 200 kb, between the markers D9S155 and D9S177. These microsatellites are 
positioned distal of the TCC1 region and proximal to the DBC1 region. In ovarian cancer, 
LOH is found around the gelsolin gene (GSN), where the DBC1 gene is expected. 
Both the TCC1 and TCC2 regions were screened for the presence of homozygous 
deletion in 17 bladder tumor cell lines with in total 100 microsatel!ite markers, with an 
average spaCing of 300-500 kb. Deletions of the CDKN2 region are often between 50-500 kb 
or more in size (204). Other homozygous deletions vary between 130 kb in B-cell chronic 
lymphocy1ic leukaemia (30), and 3 Mb in NSCLC (94). This suggests that the homozygous 
deletion targeting the TCC1 and TCC2 loci are either much smaller in size than those 
observed for other loci or that the putative TSGs are not readily inactivated by homozygous 
deletions. 
Several interesting genes in the TCC2 region are known: the Transforming Growth 
Factor 0 receptor type I gene (TGFBR1), the Death Associated Protein Kinase 1 gene 
(DAPK1) and theTuberous Sclerosis 1 gene (TSC1). Further studies to identify the genes 
involved in bladder cancer, should include these genes as candidates. 
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Abstract 
We assessed a series of bladder tumours and bladder tumour cell lines for sequence 
variation in the KrOppel-like zinc finger gene ZNF189, the Tuberous Sclerosis Complex gene 
1 (TSC1) and the TGF beta receptor type I (TGFBR1). All three genes have been mapped to 
9q regions commonly deleted in transitional cell carcinoma of the bladder. Mutation analysis 
of the coding sequence of these genes revealed several variant bands that were shown to 
represent polymorph isms. Mutation analysis of the ZNF189 gene in bladder cancer cell lines 
identified one amino acid substitution (lysine -+ isoleucine) at position 323 in exon 4. For the 
TSC1 gene, two mutations were identified in two out of 27 independent cell lines. Both 
mutations result in a truncated protein. Furthermore, one out of 36 bladder tumours had a 
frameshift mutation in exon 7 of the TSC1 gene. No tumour-specific mutations were found in 
the TGFBR1 gene. We also investigated the length of the polyalanine tract present in exon 1 
of the TGFBR1 gene. It has been suggested that the allele with 6 alanines (6A) is more 
frequent in patients with bladder and other cancers. We therefore compared bladder cancer 
patients with normal controls. In both groups the percentage of heterozygotes was 17%. 
Thus, our data do not support a role for the 6A allele in bladder cancer susceptibility. 
Introduction 
Tumors of the transitional epithelium of the bladder often present as superficial, non- or 
minimally invasive, papillary structures. The most prominent genetiC aberration in these 
tumors is loss of (part of) chromosome 9 (141). So far, several groups have tried to identify 
putative tumor suppressor genes on chromosome 9q by testing for loss of heterozygosity 
(LOH) with microsatellite markers. This approach has led to the establishment of different 
regions of loss on both the short arm and the long arm (60, 64, 82, 160, 161, 186). A further 
narrowing down of these regions has proven to be difficult because of the complicated loss-
patterns present in many tumors. Another approach therefore, would be to look for the 
involvement of candidate genes known to be located in the regions of interest. Presently, 
only a few chromosome 9 genes have been considered, including CDKN2A, GAS1, Gelsolin, 
PTCH, and DBCCR1 (61, 160, 173). Although the involvement of the 9p gene CDKN2A has 
been shown in several studies, no significant percentage of tumors has been correlated with 
a specific gene on chromosome 9q (61, 173). 
In this study, we describe the analysis of three different candidate genes located on 
chromosome 9q that could be involved in bladder cancer. The ZNF189 gene encodes a 
KrOppel-like zinc finger protein with a predicted KRAB A domain at the N terminus, a spacer 
region, and 16 zinc fingers of the Cys,His, type (124). These domains are frequently found in 
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proteins involved in transcription repression. Tuberous sclerosis complex (TSC) is an 
autosomal dominant disorder characterised by the growth of multiple benign tumors 
(hamartomas) in many tissues and organs. The TSC1 gene was identified on chromosome 
9q34 (184). The LOH observed in TSC associated hamartomas suggests that TSC1 acts as 
a tumor suppressor gene. Transforming growth factor B regulates cell cycle progression via 
binding to the type II receptor and activation of the type I receptor. Both receptors are 
transmembrane serine/threonine kinases. Various types of human tumor cells are insensrtive 
to TGF-~ mediated cell cycle arrest, suggesting inactivation of the TGF-~ signalling pathway, 
either by mutation in the type I or type II receptor. TGFBR2 mutations have been found in 
different tumor types, mostly in combination with the MIN+ phenotype (113). The knowledge 
of the tumorigenic role of the TGFBR1 gene has been limited to the identification of a single 
mutation in breast cancer metastases (23). A polyalanine stretch in exon 1 of this gene 
shows variation in length, the most frequent alleles being TP.,R-I with nine alanine residues 
and T~R-I(6A) with six alanine residues (133). Recent studies suggest a difference in 
functionality of both alleles, where the T~R-I(6A) variant could function as a susceptibility 
allele for bladder and several other types of cancer (24, 132, 133). 
Materials and Methods 
Bladder cancer cell lines and tumors 
The following bladder cancer cell lines were screened for mutations in the coding sequence 
of the candidate genes: 253J, 575A, 647V, 1207, 1266,5637, EJ, HcV29, HT1197, HT1376, 
J82, Jon, KK47, RT4, RT112, SCaBER, SO, SW780, SW800, SW1710, T24, TCCSUP, 
UMUC3, VMCubl, VMCubll, VMCublll, VT (available from ATCC or DNA kindly provided by 
Dr. F. Radvanyi). Genomic DNA was prepared according to standard procedures (145). 
Thirty-six archival, paraffin-embedded tumours (10xTa, 9xT1, 14xT2, 3xT3) were tested for 
mutations in the TSC1 gene. DNA was isolated as described previously (186). 
Microsatellite analysis 
Microsatellite analysis of the bladder cancer cell lines was done as previously described 
(186). At least six different informative polymorphic markers for chromosome 9 were tested 
per cell line. 
Mutation Analysis and sequencing 
Primers for the ZNF189 gene were as follows: exon 1: 5'-CCCAATTCCTGCCCCTA TTC-3', 
5'-AAAGCAGTGCGGCCTA-3', exon 2: 5'-GGTTCGCGAACAAACTGC-3', 5'-
CTTGGGGTCCAGGCACTGAG-3', exon 3: 5'-CCTCTGTCACTTTTAGTGG-3', 5'-
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CAGTGAGACCAGGTrTCC-3', exon 4A: 5'-GAACAGAGATAAGGATGAGG-3', 5'-
TrTATGGGGTCTrTCCCCAG-3', exon 4B: 5'-CCAACTCAGAGAGAAATGC-3', 5'-
CTGCTGTATAACAAGACTGC-3', exon 4C: 5'-CCAGGGAGAAGACTTATCC-3', 5'-
GGTACTAGTCTCAAATCAAATTG-3'. For TSC1, primer sequences for amplification of the 
21 coding exons (exon 3-23) were obtained from 
http://expmed.bwh.harvard.edu/projects/tsci. For exon 15,21,22, and 23, new primers were 
designed (exon 15: 5'-GTAAAGGCTCAGGGTTCACG-3', 5'-CGTGAACCCTGA 
GCCTrTAC-3', 5'-AGGCTGCCCGCTTCCAAAG-3' 5'- CTrTGGAAGCGGGCAGCCT-3', 
exon 21: 5'-CACAAAAGCCTrTCCTGATG-3', exon 22: 5'-CATCAGGAAAGGC TTTTGTG-3', 
exon 23: 5'-TTGAACTGGGAAGTGAGCCC-3', 5'-GGGCTCACTTCC CAGTTCAA-3') to be 
able to amplify DNA isolated from the paraffin-embedded tumors. The primers for the 
TGFBR1 gene were adapted from Vellucci and Reiss (188). PCR conditions were 
standardised at 35 cycles of 95°C for 30', 55°C for 30', and 72°C for 30', with the addition of 
U_32p dATP. Amplification products were analysed for heteroduplex formation using weakly 
denaturing polyacrylamide gels (29:1 acryl:bisacryl) (32), or via single strand conformational 
polymorphism (SSCP) at room temperature with 6% polyacrylamide gels (49:1 
acryl:bisacryl). Since in the case of cell lines, no normal control DNA of the same patient 
could be used and most of the cell lines are hemizygous for regions on chromosome 9q, we 
mixed the amplified DNA of two different samples prior to the formation of heteroduplexes. 
Aberrant bands were isolated from the acrylamide gels by incubating the slice in water for 
three hours at 37"C, followed by reamplification and sequencing using the Sequenase 
sequencing kit (USB, Cleveland, Ohio). For the polyalanine stretch in exon 1, primers were 
used according to Pasche et a/. (133), Because of the high CG-content of this part of the 
gene, we used the Clontech GC-melt kit (Clontech, Palo Alto, CAl in combination with a 
touchdown PCR in the presence of a_32p dCTP. 
Statistical analysis 
Frequency distribution data were analysed by the Chi-square test. A p-value of <0.05 was 
considered significant 
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Results 
Mutation analysis for the three candidate genes was done by SSCP and Heteroduplex 
Analysis (HDA) in 27 bladder tumor cell lines and, for TSC1, in 36 bladder tumors. Since 
many of the cell lines used will have LOH for the studied regions of chromosome 9, the 
hetero- or homozygosity of chromosomes 9 regions in 20 different bladder cancer cell lines 
was determined with a series of highly informative microsatellite markers. This is depicted in 
Figure 1. LOH of a region was deduced when three or more closely spaced markers 
revealed only one allele. 
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Figure 1. Determination of the chromosome 9 status of 20 bladder cancer cell lines with microsatel/ite markers 
and sequence determination. Gel/lines 253J, HT1376. KK47, TCGSUP, VMCubll, VMGubllJ and VT were also 
included in the mutation screening. At least six different informative polymorphic markers for chromosome 9 were 
tested per cel/line. The chromosomes are represented by lines. The genes ZNF189. TSC1 and TGFBR1 are 
represented by circles. InformatMty is indicated by a circle on both chromosomes. A dotted fine is given when the 
hetero~ or hemizygous state is unknown. Loss is represented by a gap in the chromosome. Mutations are 
indicated with a black circle. Polymorphisms are given in grey circles. For a description of the polymorphisms or 
mutations, see text. 
For HDA, cell line DNA but also mixtures of DNA samples from two different cell lines were 
used to circumvent the possibility that mutations would go undetected because of LOH of the 
region of interest. Several aberrant bands were found in the coding sequence of the ZNF189 
gene (results not shown). Figure 2A and Figure 2B show two polymorphisms, Figure 2C 
shows the only mutation found in this gene. The effect of this mutation on the function of the 
protein is unknown. Table 1 summarizes the mutations and polymorphisms found. 
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Figure 2. Sequence analysis of mutations found in bladder tumor cell lines. A; A G/,f. polymorphism is present in 
exon 1 bp 12 of the ZNF189 gene in cell line HT1197. B; in exon 4 of the ZNF189 gene, a G/A polymorphism was 
found at bp 1602. Cell line 5W780 is heterozygous at this position. C; an aminoacid substitution was found in celf 
line VMCubl at position 323 replacing a lysine with isoleucine (bp 969, AAA -)- ATA). 0; A 1 bp deletion causes a 
frameshift mutation in exon 15 of the TSC1 gene in bladder tumor cell line RT4 and a stopcodon at amino acid 
701. E; A C-T transition in exon 4 ofTSC1 causes a stopcodon at aa 54 in bladder celf line HcV29. 
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Table 1 also summarizes the results of the TSC1 mutation screening. We found a one-
basepair deletion in exon 15 (1890LlC) in cell line RT4 (Figure 2D). This mutation has been 
reported before in bladder cancer (71). A second mutation was found in exon 4 in cell line 
HcV29 (Figure 2E). Furthermore, 36 tumors were included in the analysis. One patient had a 
mutation in exon 7 (data not show), resulting in a frameshift. In total, three mutations (2 out of 
27 cell lines, 1 out of 36 tumors) were found in the TSC1 gene. 
Gene 
ZNF189 
TSC1 
Table 1, Alterations in ZNF189 and TSC1 found in 
bladder cancer eel/lines and bladder cancer patients. 
Cel! line/tumor Mutation 
HT1197, VMCubll, VMCubll1 Exon 1, 12G>A 
24 of 27 cel! lines Exon 4, 1602G>A 
VMCubl Exon 4, 969A> T 
RT4 Exon 15, 1890deJC 
HcV29 Exon 4, 384C> T 
1207, SD, VMCubJlJ, tcc20, tcc56 Exon 22, 3050C> T 
tcc42 Exon 7, 747lnsT 
Consequence 
Polymorphism 
Polymorphism 
K>l substitution 
Frameshift 
stopcodon 
Polymorphism 
frameshift 
Exons 2-8 were used for HDA of the TGFBR1 gene. Primers for amplification were adapted 
from Vellucci and Reiss (188). No mutations or polymorph isms were found in the 27 tested 
cell lines. The analysis of the polyalanine tract present in exon 1 showed two of the four 
different alleles as were published by Pasche et a/. (133). A complete absence of the 
polyalanine tract was observed in cell line RT4, Furthermore, the allele distribution was 
determined in a control population and a group of bladder cancer patients, An overview of 
the allele distribution is given in Table 2. In both our populations of random 'Individuals and 
patients with TCC, the frequency of the T~R-I(6A) allele is significantly higher than previously 
reported, 17.5 and 17.1%, respectively. Our findings, in contrast to those of Pasche et a/., 
suggest that the T~R-I(6A) allele does not predispose towards the development of bladder 
cancer. 
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Table 2. Frequency of the pofyafanine tract polymorphisms in normal blood donors, 
bladder cancer eel/lines, and peripheral blood lymphocytes of bladder cancer patients. 
Samples 9PJ9A 
Normal blood donors 148 
PBl of TCC patients 121 
Discussion 
9PJ6A 
32 (17.5%) 
25 (17.1%) 
6PJ6A 
3 
o 
In this study we describe the mutation analysis of 3 9q genes in bladder cancers and bladder 
cancer cell lines. LOH of 9q is a very frequent finding in these tumors. suggesting that a 
gatekeeper gene for bladder cancer is located on this chromosome arm, Indeed, our analysis 
of the bladder tumor cell lines shows that 13 out of 20 cell lines display chromosome 9q 
aberrations, Unfortunately however, so far no gatekeeper role could not be assigned with 
certainty to any of the genes from this chromosome that have been investigated, Likewise, 
our study excludes an important mutational contribution from the ZNFI89, TSCI and 
TGFBRI genes. The sensitivity of the methods used (SSCP and HDA) is around 80%, 
meaning that we could have missed some mutations. Even when this is taken into account, 
the number of mutations in the genes tested here will be too low to support a significant role 
in bladder pathogenesis. However, when considering the ZNF189 gene we cannot 
completely rule out the possibility that mutations causing bladder cancer are preferentially 
located in another part of the gene, especially since it has been suggested that the gene has 
more exons than the 4 that were published initially (124). Our percentage of TSC1 mutations 
in bladder cancer is lower than the 10% found by Hornigold et al. (71). A possible 
explanation for this could be that we did not select for tumours with LOH at the 9q34 region. 
The TGFBRI gene comprises a polymorphic alanine stretch in its first exon. Alleles 
with 5, 6, 9 and 10 alanines have been observed in the population, with the 9A allele being 
the most frequent. When Pasche et al. compared the frequency of the TBR-I(6A) allele in a 
control population with a group of patients with different types of cancer, they found a 
significantly higher frequency of this allele in the cancer patients (133). From this work, they 
conclude that the 6A allele is a candidate tumor susceptibility allele. In addition, their 
experiments suggest that the protein with 6 alanines is less active in signal transduction, 
providing a logical explanation for the association of the 6A allele with cancer predisposition. 
These authors observed 13% and 10.6% 6PJ9A heterozygotes in bladder cancer patients 
and the control population, respectively. However, in contrast, in the study described here we 
observe percentages of 17% for both groups. The 17% in the control population is much 
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higher than the 10.6% heterozygotes in Pasche's control group and even higher than the 
average percentage of 14.6 that they observe in all cancer patients together. It is not clear 
how the discrepancy between their and our findings can be explained. Analogous to their 
study, our control group is approximately 20 years younger than the bladder cancer cases 
and consists of people that donated blood to screen for recessive hereditary non-cancer 
diseases. Because of privacy reasons we have no further information about these people, 
however, we have no reason to think that this group harbours a high percentage of future 
cancer patients or that the ethnic make up of both groups differs significantly. Therefore, we 
must conclude that our data do not support a role for the TGFBR116A allele in a 
predisposition towards bladder cancer. 
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Molecular evolution of recurrent bladder cancer 
Abstract 
We describe the reconstruction of bladder tumor development in individual patients spanning 
periods of up to 17 years. Genomic alterations detected in the tumors were used for 
hierarchical cluster analysis of tumor subclones. The cluster analysis highlights the clonal 
relationship between tumors from each patient. Based on the cluster data we were able to 
reconstruct the evolution of tumors in a genetic tree, where tumors with few aberrations 
precede those with many genetic insults. The sequential order of the tumors in these 
pedigrees differs from the chronological order in which the tumors appear. Thus, a tumor with 
few alterations can be occult for years following removal of a more deranged derivative. 
Extensive genetic damage is seen to accumulate during the evolution of the tumors. To 
explain the type and extent of genetic damage in combination with the low stage and grade 
of these tumors, we hypothesize that in bladder cancer pathogenesis an increased rate of 
mitotic recombination is acquired early in the tumorigenic process. 
Introduction 
Tumorigenesis is a process that is largely occult. It is generally accepted that most cancers 
will develop through an accumulation of mutations in oncogenes and tumor suppressor 
genes, a process, which precedes clinical detection of the tumor. The tumor that is finally 
clinically detected is more often than not a heterogeneous mixture of cancer cell subclones, 
which makes it difficult to establish the order of the genetic insults. The postulated steps in 
tumorigenesis are almost invariably based on a retrospective comparison of genomic 
alterations in tumors from different patients of different stage and grade. Early steps are then 
defined as genetic alterations that are present in all grades and stages, whereas later steps 
are detected solely in the higher stages and grades. The prototype for genetic evolution in 
cancer is presented by the colon cancer model that describes the distinctive stages from 
benign adenoma through carcinoma by successive alterations in APe, KRAS, TP53 and a 
gene on chromosome 18q, respectively (45). The only example so far, in which neoplastic 
development was monitored in time in one and the same patient by repeated biopsies, is 
Barrett's esophagus, a premalignant condition that predisposes to esophageal 
adenocarcinoma. In these patients regions of metaplasia, low- and high-grade dysplasia and 
adenocarcinoma can be distinguished in the same area. These histologically distinct stages 
are clonally related and presumably derived from a single precursor and a model for the 
genetic evolution of these different stages has been designed (5, 49). 
Bladder cancer is a disease that presents as superficial in -75% of patients. Although 
these papillary tumors that extend into the lumen of the bladder are easily removed by 
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transurethral resection (TUR), as many as 60-80% of patients will eventually develop one or 
more recurrences (96). New tumors arise most of the time at a different location and are not 
regrowths of an incompletely removed tumor (67). The multiple recurrences are most 
probably clonally related as appears from X chromosome inactivation studies and genetic 
and cytogenetic analyses (43, 158). Therefore, these tumors are the result of dissemination 
and re-implantation of tumor cells in the bladder wall and/or of spreading of tumor cells via 
expansion within the urothelium. Due to this rather unique property, bladder cancer provides 
the opportunity to study the genetic relation and evolution of the different tumor subclones 
over long periods of time in one and the same patient because of their separate locations. 
Previous genetic studies of bladder cancer established that the most frequent alterations 
represented by loss of heterozygosity (LOH) are on chromosomes 4p, 8p, 9p, 9q, 11 P and 
17p (7, 88, 157, 170). Furthermore. it has been found that recurrent tumors may have both 
concordant and discordant genetic alterations, suggesting that genetic evolution is an 
ongoing process in tumor development (169). However, a thorough description of the tumor 
evolution process is still lacking. In this study, we explored the unique possibilities of bladder 
cancer as a model for cancer evolution in general. To this end, we systematically mapped 
the individual tumor genotypes of 11 patients with 104 recurrent bladder cancers. 
Materials and Methods 
LOH analysis 
LOH was assessed with the following polymorphic markers or gene markers: 02S423, 
02S405, 02S1326, 02S1397, 04S186, 04S230, 04S243, FGA, FGFR3, 05S492, ACTBP2, 
08S258, 08S298, 09S171, 09S153, 09S152, 09S252, 09S278, 09S283, 09S1816, 
09S280, 09S1851, 09S180, 09S176, 09S747, 09S275. 09S195, 09S242. 09S752, 
09S1826, 010S168, 010S575, 010S676, 010S169, 011S1776, 011 S4200. 013S802, 
014S288, 014S267, 017S695, 017S960, 017S786, 018S51, 022S686, 022S685, 
022S684, 022S683, 022S445, 022S444, or nrs 1-49, respectively, as used in Figure 1. 
Primers were chosen in regions with relative frequent losses in bladder cancer. Markers on 
chromosome 2 and 22, which, so far, did not show many changes in bladder cancer, served 
as controls. Primer sequences were obtained from the Genome Database 
(http://gdb.www.gdb.org) or the Cooperative Human Linkage Consortium 
(http://lpg.nci.nih.gov/CHLC) and were chosen for their high degree of inforrnativity and for a 
clear visualization of the alleles (Le. as few stutter bands as possible). In most cases ratios of 
upper and lower alleles were quantified using the Phosphor Imager (Molecular Oynamics, 
Sunnyvale, CAl. All LOHs were performed in duplicate. Phosphor Imager graphs without 
clear peaks, due to low signal intensities were dismissed and the marker was considered not 
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evaluable. LOH was defined when the ratio between the upper and lower alleles in tumor 
DNA was <0.6 or >1.67 when compared with control DNA: (T1fT2) 1 (N1/N2) = ratio. Note 
that this distinguishes between losses of upper versus the lower allele. This representation 
was deemed necessary because of the obseNed alternate allele loss in some patients. A 
calculation of all losses shows that lower and upper alleles are lost with similar frequency. 
This indicates that our approach is valid because there is no preference for loss of, for 
instance, the upper, sometimes naturally weaker, allele. Approximately 40% of the LOH 
ratios were <0.3 or >3.33. Changing the cut-off values to 0.3/3.33 did not significantly alter 
the results. Detailed information is available online as supplementary data. 
Human tumor tissues 
We selected 104 paraffin-embedded bladder tumor specimens from 11 different patients with 
five or more recurrences. Sections were examined microscopically by a pathologist (Th. v/d 
K). Parts that represented tumor tissue were punched out of the original paraffin blocks. In 
general the percentage tumor tissue in the material dissected by this procedure was 
estimated to be >90%. Normal bladder epithelium of the same patient seNed as a 
constitutive control for each patient. A group of unrelated blood DNA samples was analyzed 
for all markers in order to correct for variation in ratio between allele~specific combinations 
and to seNe as alternative control in those instances where the normal epithelium DNA was 
not reliable or unavailable. DNA isolation was done as described previously (186). 
Mutation analysis 
Patients were screened for the recently described mutations in the FGFR3 gene (20) (exons 
7, 10 and 15) with SSCP-analysis at room temperature on 6% polyacrylamide gels (49:1 
acryl:bisacryl) or amplification products were analyzed for heterodupiex formation using 
weakly denaturing polyacrylamide gels (29:1 acryl:bisacryl) (32). The nature of the mutation 
was confirmed by subsequent sequence analysis. Dr. F. Radvanyi kindly prov'lded primers 
for the FGFR3 exons 7, 10 and 15. 
Cluster analysis 
We used the cluster analysis program available at http://rana.stanford.edu/software to apply 
a hierarchical clustering algorithm to the tumors. The starting data table consisted of the 
following options: 0; retention, -1000; loss of the upper allele, 1000; loss of the lower allele, 
500; MIN, -500; point mutation in the FGFR3 gene. The result of this process is a 
dendrogram in which short branches connect similar genotypes and longer branches reflect 
diminishing similarity. To avoid confusion with micro~array results, we chose to change the 
colors to yellow and blue for loss of the upper and lower allele, respectively. 
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Results 
A total of 48 microsatellite markers were used to determine a genotype for each tumor based 
on the number and nature of markers with LOH. In addition, the FGFR3 gene was screened 
for specific point mutations. The LOH data were re~interpreted to be used for a one~ 
dimensional hierarchical cluster analysis as described by Eisen et al. (38). Figure 1 shows 
the results of such an analysis when all 104 tumors are used for clustering based on the LOH 
and mutation analysis results, Patients in the figure are identified by colors next to the 
dendrogram. From this figure it is evident that the tumors from one patient tend to cluster 
together. For instance, 13 of the 15 tumors from patient 61 cluster in one sub-branch of the 
cluster dendrogram. Therefore these results suggest that tumors from one patient are more 
related to each other than tumors between patients, providing further support for a 
monoclonal process of tumorigenesis. 
Subsequently, we assessed the relationships between the different tumors of single 
patients. Figure 2A shows the number, stage and grade of the 15 bladder tumors from 
patient 22. These tumors were removed between 1977 and 1990. Identification number, 
stage and grade of the tumors are indicated. Tumors are ordered in a chronological order, 
i.e. tumor A was removed before tumor B and so on. Twenty-nine microsatellite markers 
were informative for this patient and 17 showed LOH in one or more tumors, ranging from no 
loss to a loss of 11 markers. The extent of loss is indicated by the ratio between upper and 
lower alleles as calculated by the Phosphor Imager. 
Figure 1. (next page) Cluster analysis of 104 tumors from 11 patients shows that the different tumors from one 
patient are clonally related. The color bar underneath the dendrogram depicts the different patients. These are 
represented by different colors (patient number and color are indicated on the lower right). The length of the 
branches represents the relation between individual tumors, i.e. short branches descending from a node indicate 
highly related samples. The scale on top is a quantification of these relations, with -1 indicating no relation and +1 
the maximal relation. In the array table the different genetic aberrations used for the calculation are depicted as 
indicated underneath the table. The genetic markers are shown on top of the table and for reasons of clarity they 
are numbered from 1 to 49. Their identity can be found in the materials and methods section. Note that the 
relatively large proportion of gray cells in the table is due to the fact that in this analysis al/ markers had to be 
used for the cluster analysis, including the markers that were not informative for a given patient 
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An identical point mutation in the FGFR3 gene was detected in 10/15 tumors. When the 
genetic aberrations seen in the individual tumors of this patient are compared, it is clear that 
these cannot be explained by a linear model based on the chronology of appearance, simply 
because consecutive tumors have genotypes of different complexity. For example, no 
genetic alteration was seen in tumor I, removed in 1985, while previously resected tumors A-
H all displayed loss of one or more markers and/or had a mutation in the FGFR3 gene. Note 
also that these losses do not appear to be random and unrelated, since for most markers 
LOH in different tumors concerns the same allele. We then reordered the tumors with respect 
to genetic events. A representation of the data based on a one-dimensional cluster analysis 
is given in Figure 2B. The scale next to the dendrogram indicates the correlation coefficient 
calculated by the program. From this calculation it appears that all tumors except I are 
considered to be highly related. Because the cluster analysis does not provide a direction to 
the tumor evolution process, we then reordered the tumors based on the cluster data but with 
the assumption that a tumor with no or little genetic damage will have evolved before a tumor 
with extensive damage. In addition, this handmade reconstruction allows the introduction of 
hypothetical steps in the evolution process. The resulting evolutionary tree of the tumors in 
patient 22 is depicted in Figure 2C. Tumor I is considered to be the primary tumor and, for 
instance, tumor B, which was removed 7 years before I, as a descendant from tumor I. As 
can be seen in Figure 2B and C, B is several genetic steps removed from I. Based on this 
analysis, we propose that the genetic tree reflects the development of, and relationships 
between, the different tumors from this patient better than the linear chronological order in 
which the tumors were removed. 
Patient 61 also developed 15 tumors between 1976 and 1990. Twenty-four markers 
were informative and of these 16 showed LOH in one or more tumors, with a maximum of 8 
markers with LOH in a single tumor (Figure 2D). Again, the genotypes of the tumors suggest 
a different order in genetic events than their chronological appearance. The strikingly 
consistent loss of the lower allele of D103169 in all tumors indicates that loss of this marker 
is the first or a very early event and that a clonal relationship between recurrences is very 
likely. An identical FGFR3 mutation was observed in 14/15 tumors. In Figure 2E the 
clustered analysis is shown. In this patient, the correlation coefficient between tumors ranges 
from 0.05 to -1, again suggesting an intimate relationship between these tumors. As for the 
previous case, we then reconstructed the tumor clustering assuming a direction in the 
genetic build-up and by the introduction of hypothetical genetic steps. The adjusted tumor 
tree representing the genetic pathways along which the recurrences have developed in 
patient 61 is shown in Figure 2F. All tumors derive from tumor L, since in this tumor only one 
genetic insult was detected. Tumor A from patient 61 was removed in 1976 and tumor L in 
1987. Tumor A has many additional genetic aberrations that are lacking in L. 
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Figure 2. Genotypes, hierarchical tree clustering and deduced evolutionary trees for the multiple tumor 
recurrences from patient 22 and 61. For an explanation of colors, see Figure 1, with the exception that in Figure 
2A and D retention is indicated by white cells. A, LOH analysis and genotypes of the 15 tumors in patient 22. 
Tumors are ordered chronologically in columns, microsalellite data and FGFR3 mutation analysis in rows. 
Markers are ordered per chromosome from pter to qter, non·informative markers were excluded. B, cluster 
analysis of the tumors. One-dimensional hierarchical clusten'ng was performed using the genetic data from A. C, 
evolutionary genetic tree depicting the relationship between the recurrences of patient 22. Each circle represents 
a tumor. Arrows indicate the different genetic steps and the markers involved are listed next to each arrow. 
Because of the alternating losses observed for some markers, an asterisk indicates whether the upper or lower 
al/ele is lost, when relevant. D, genotypes and LOH analysis of the 15 tumors in patient 61. E, clustered 
correlations between recurrences. F, evolutionary genetic tree of patient 61 . 
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Figure 3. (previous page and above) Cluster dendrograms and reconstructed genetic trees of the remaining eight 
patients. For reasons of clarity, markers are depicted without the initial letter D. Because of the alternating losses 
obseNed for some markers, asterisks indicate whether the upper or lower allele is lost. The scale on the right can 
be used to estimate the degree of genetic relation. A complete description of the genetic analyses can be found 
online as supplementary information .. 
Thus, in the genetic tree, L precedes A. It can be seen in Figure 20 that tumor L is a mixture 
of CIS and Ta. Considering the extent of LOH, loss of D10S169 is most probably present in 
all cells of this tumor. The intenSity of the SSCP signal, however, suggested that the FGFR3 
mutation was restricted to a fraction of the tumor (results not shown). We therefore divided 
tumor L in the fraction with mutation (L) and the fraction without receptor mutation (La). In the 
model, La is the founding tumor moiety, giving rise to S, the only tumor without the FGFR3 
mutation and L, from which the remaining tumors derive (Figure 2F). 
We were able to establish such a representation of sequential events, linking the 
tumors to one or more common precursor clones, for all patients, except one. In the six 
tumors from this latter patient (no. 32) in total only seven genetiC hits were scored and this 
number is too low for a reliable cluster analYSis. A representation of the cluster data and the 
deduced genetiC trees for the other eight patients is given in Figure 3. In two of these 
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patients, a first tumor was detected from which all other tumors developed. For the others, a 
hypothetical first tumor or tumor cell has been assumed. It also appears that for only one 
patient (patient 30) the first clinically presenting tumor (tumor A) is also the founding tumor in 
the genetic pedigree (Figure 3). When the positions of the tumors in all trees are compared 
to their clinical manifestation, it is apparent that the chronology of tumor presentation does 
not parallel the genetic evolution of the tumors at all. Thus, this appears the leading principle 
rather than an exception. 
Although most losses in the tumors from a certain patient concern the same allele, 
alternate allele loss was found for 19% of the LOHs in total (indicated by superscript and 
subscript asterisks in Figure 3). Especially in patient 23, the alternate allele loss is very 
pronounced and concerns 10 of the 28 markers with LOH. This results in a more extensive 
branching of the tree than for the other patients. 
Discussion 
An accumulation of mutations in essential genes can transform a normal cell into a cancer 
cell. This transformed cell may then grow out to form a tumor with additional mutations 
occurring during this process. The tumor that is finally clinically detected is more often than 
not a heterogeneous mixture of cancer cell subclones, which makes it difficult to establish the 
order of the genetic insults. Bladder cancer, however, provides the unique property that 
different tumor subclones grow at separate sites and thus can be studied independently. The 
presence of identical alterations in different bladder tumors from one patient and the increase 
in the number of genetiC alterations allowed us to order the multiple tumors in each patient in 
the form of evolutionary genetiC trees or pedigrees. In such a model, an original transformed 
cell grows out and sheds cells into the lumen of the bladder. Some of these cells will have 
acquired additional genetiC damage. They attach to the bladder wall, grow out and can 
themselves lead to secondary disseminations and so on, thus creating the different branches 
of the tree. This model resembles the evolution of cell lineages in Barrett esophagus (5). In 
their model esophageal adenocarcinoma evolves from premalignant conditions such as 
metaplasia and dysplasia. Their results also indicate that this clonal evolution is more 
complex than predicted by a linear model. Here we show that bladder cancer cell lineages 
evolve, like in Barrett's model, over a period of many years, g·lving rise to clonal expansion 
and outgrowth due to newly acquired aberrations, and continue to do so after the emergence 
of recurrent tumors. 
Interestingly, it appeared that the chronology of tumor appearance does not run in 
parallel with the genetic evolution. This also implies that the earliest genetic events must be 
deduced from the genetic tree rather than from the first appearing tumor. Thus, the 
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evolutionary trees could theoretically lead to the identification of a common first or early 
genetic step for these supenftcial bladder tumors. However, it appears that in the early steps 
of the trees from the 11 patients represented here, no evidence for a common first LOH 
event can be identified. We rather suggest that the extensive LOH found is due to random 
genomic instability, appearing already very early in the development of superficial bladder 
cancer. In some of the pedigrees theoretical early tumors/tumor cells have been introduced. 
A second question that can be raised is whether there is a certain identifiable genetic step 
that can lead to the clinical appearance of a tumor, Le. a step that, for instance, induces rapid 
growth. Again the pedigrees do not reveal such a common denominator. 
The standard treatment for low-stage, low-grade bladder tumors involves TUR, 
although there appears to be a general agreement that TUR alone does not prevent the 
development of new tumors. TUR is therefore often followed by intravesical treatment with 
bacillus Calmette-Guerin (BCG) in order to provoke an immune response that is thought to 
lead to rejection of urothelium and remaining tumor cells. Besides possible differences in 
growth rate, this might, at least to some extent, explain why an apparent precursor with few 
alterations appears so much later than a descendant subclone. Any tumor that reaches the 
detection threshold at a certain point in time will be removed and, subsequently, all other 
existing, but not yet visible, subclones will be affected or even wiped out by the adjuvant 
treatment. 
A surprising finding is the sheer number of alterations in some tumors. There is a 
great variability in the number of LOH events that was observed per tumor, ranging from 
none or a few alterations in the early steps of the genetic trees to LOH of 65% of the 
informative markers. When these numbers are extrapolated it appears that a large part of the 
genome may be affected. A related extrapolation has recently been presented by Stoler et al. 
(168). In their paper the authors show that colonic polyps, representing early steps in the 
tumor progression pathway, have a mean number of 11,000 genomic events per cell. Our 
findings also illustrate that the number of genomic alterations even in early tumor stages is 
already astoundingly complex. These findings can best be explained by assuming that 
genomic instability is already present early in tumorigenesis. 
There are two levels of genetiC instability: at the nucleotide level (microsatellite 
instability or MIN) and at the chromosome level (chromosome instability or CIN), the latter 
being much more frequent in cancer (101). We found microsatellite instability in 19 tumors, 
but only few of these showed instability for several markers. In general, MIN is not 
considered to playa major role in bladder cancer (55), although it is reported to be more 
frequent in young patients with bladder cancer (26). What type of instability mechanism could 
best explain the findings presented here? It appears that the LOH events that we observe on 
the best studied chromosome, chromosome 9q, reveal what can best be described as a 
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patchwork pattern of losses and retentions, rather than loss of an entire chromosome or 
chromosome arm. For instance, in patient 22 (Figure 2C) loss 09S283 is followed by loss of 
09S275 and 09S752; moreover, all 3 areas of loss increase in size as is apparent from 
subsequent losses of adjacent markers. Likewise, in patient 61, LOH of the marker 09S1851 
is followed by losses of the adjacent markers 09S1816 and 09S278. However, in the case of 
these latter markers loss of alternate alleles occurs in different tumors. To explain these 
findings, we suggest a model in which the losses of heterozygosity are caused by an 
increased rate of mitotic recombination. Recombination between two homologous chromatids 
during mitosis could result in multiple crossovers (35). As a consequence, the crossover 
region in the recipient chromosome becomes identical in sequence to the donor 
chromosome. When recombinations occur frequently this leads to an expansion of the region 
of loss of heterozygosity. A model to explain this mechanism is given in Figure 4. 
Possible socond 
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Figure 4. Enhanced rates of mitotic recombination may create multiple regions of LOH and expand existing LOH. 
The recombination takes place between homologous chromatids. For reasons of clarity, sister chromatids are not 
included. The arrows next to the chromosomes indicate the extent of LOH. 
The consequence of mitotic recombination is that no actual loss of chromosome regions 
occurs; only the sequence of part of one chromosome is now an exact duplicate of the other. 
Thus, the tumor genome in later stages of the genetic tree becomes more and more 
homozygous. Such a mechanism would be compatible with the low-stage, low-grade 
phenotype of the papillary bladder tumors. Although some of the LOH events could perhaps 
be explained by tetraploidization followed by loss of a chromosome, we believe that this is 
not the major explanation for our findings for the following reasons. Firstly, this would not 
explain the patchwork nature of the losses; secondly, in >40% of the cases, the LOH is far 
too profound; and thirdly, fiow cytometry of bladder cancers has shown that especially the 
low-stage, low-grade papillary tumors, like the ones in this study, are mostly diploid (175). 
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An enhanced rate of mitotic recombination is seen in hereditary syndromes like 
Bloom's syndrome, Fanconi anemia and Werner's syndrome (37, 98, 207). The pattern of 
chromosome instability in especially Bloom's syndrome is characterized by sister-chromatid 
exchanges and homologous chromatid interchanges reflected in a gain of homozygosity for 
polymorphic loci (40, 59). Patients with these diseases have an increased risk of developing 
several cancers. The genes responsible for these syndromes have, in part, been cloned and 
the protein products of both the BLM and WRN genes are DNA helicases (58, 81). 
Therefore, we reason that it is not unlikely that a gene that functions in these diseases or a 
gene with similar characteristics may playa role in bladder cancer pathogenesis. Because of 
the increase in LOH with each step in the genetic trees, we favor a model in which such a 
type of genomic instability, caused by an enhanced rate of mitotic recombination generating 
functional homozygosity, occurs early in tumor evolution and may even be the elusive first 
step. 
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Variable 9q losses 
Abstract 
Allelic loss on chromosome 9q is a very frequent event in bladder carcinogenesis. In recent 
years, efforts have been directed towards identifying the responsible genes on this 
chromosome arm by deletion mapping and mutation analysis of candidate genes. Here we 
describe the genesis and development of chromosome 9q alterations in multiple recurrent 
superficial bladder cancers of 10 patients. We show that loss of heterozygosity on this 
chromosome is almost never the characteristic first step. The regions of loss are multiple and 
variable in different tumors of the same patient and expand in subsequent tumors. Moreover, 
the regions of loss vary form patient to patient. We conclude that, even when 9q harbors a 
bladder cancer gatekeeper gene, it is unlikely that the gene will be identified through LOH 
analysis alone. 
Introduction 
Loss of one copy of a tumor suppressor gene can create a hereditary predisposition to 
cancer. The second copy of the gene can be inactivated in many ways, such as loss of a 
(part of a) chromosome or chromosome arm. The key insight in this process came from a 
rare type of human cancer, retinoblastoma, which arises from cells in the body that are 
transformed by an unusually small number of mutations. Polymorphic markers have been 
very useful in linkage analysis in hereditary cancer syndromes, leading to the identification of 
what are often called gatekeeper genes like APe or RB. Tumor suppressor genes detected 
in hereditary cancer syndromes frequently play a role in sporadic tumors as well. These 
tumors can have loss of heterozygosity (LOH) in the area where the gene is located. This is 
relatively easily detected by screening tumor DNA with polymorphic markers. Many 
investigators therefore searched for loss of heterozygosity in their tumor type of interest in 
orderto pinpoint the location of putative tumor suppressor genes. 
Bladder cancer usually presents itself as a superficial, papillary tumor of the 
transitional cells of the urothelium. The tumors are low stage, low grade and can be removed 
by transurethral resection. However, about 70% of patients will develop one or more 
recurrences, a process that can continue for many years and eventually may lead to invasive 
disease in 15-25% of patients. It has been suggested that chromosome 9 harbors several 
genes that playa role ',n the early steps of bladder cancer pathogenesis. This theory stems 
from the observation of chromosome 9 underrepresentation by in situ hybridization (ISH) 
(135, 140, 149), comparative genomic hybridization (CGH) (78, 196) and LOH. This 
underrepresentation is sometimes seen as the sole abnormality, and can be found in tumors 
of low stages and grades. 
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On the short arm of chromosome 9, the CDKN2A gene was thoroughly investigated 
as the target of LOH (127, 204). Although the gene does not appear to be frequently 
mutated, it is often homozygously deleted or transcriptionally silenced in bladder cancer. On 
the long arm, LOH analyses so far show a multiplicity of events suggesting to some authors 
that chromosome 9q might harbor 2, 3 or even 4 genes that may have a role in bladder 
cancer (17, 34, 36, 60, 64, 82, 108, 186). Tumor suppressor genes like PTCH and TSC1, 
both found by a combination of linkage analysis and LOH in hereditary syndromes, are, 
although located in candidate regions, not frequently mutated in bladder tumors' (71, 160). 
The only candidate tumor suppressor gene on this arm found in bladder tumors at the 
moment is the DBCCR1 gene (61). This gene was found in a homozygously deleted region 
and although it appears to be transcriptionally silenced in bladder cancer, no inactivating 
mutations have been found. One of the explanations for the difficulty of finding a single 
smallest region of overlap could be that there are different subgroups of bladder tumors with 
different loss patterns, one being the continuously low grade papillary tumors, the other being 
the more invasive tumors, including carcinoma in situ. Therefore, investigators have been 
dividing tumors in separate groups with different stages and some suggest that the role of 
chromosome 9 is more important in the (non-invasive) superficial group (141,159,165). Only 
a few studies have looked at losses in tumor recurrences, mainly because for a long time it 
was suggested that bladder cancer is a field cancerization process, even after X-
chromosome inactivation studies showed otherwise (67,158). 
We previously showed that recurrent tumors in a patient are clonal and can be 
arranged in a genetic tree based on their genetic relationships. In these trees, tumors with 
few aberrations precede those with many (Chapter 5). The trees refiect the history of tumor 
development and allow the identification of the earliest genetic events that must have 
occurred in tumor evolution. We have used this background to study the development of loss 
of heterozygosity on chromosome 9q in 11 patients. We show that loss on this chromosome 
arm is almost never the characteristic first alteration in recurrent bladder cancer. The regions 
of loss are multiple and variable in different tumors of the same paflent and their size 
expands in subsequent tumors. Moreover, the regions of loss vary form patient to patient. 
We conclude that, even when 9q harbors a bladder cancer gatekeeper gene, it is unlikely 
that the gene will be identified through LOH analysis alone. 
Materials and Methods 
Tumor samples 
We selected paraffin-embedded bladder tumor specimens from 11 different patients with five 
or more recurrences. Sections were examined microscopically by a pathologist. Parts that 
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represented tumor tissue were punched out of the original paraffin blocks. In general the 
percentage tumor tissue in the material dissected by this procedure was estimated to be over 
90%. Normal bladder epithelium served as a constitutive control for each patient. A group of 
unrelated blood DNA samples was analyzed for all markers in order to characterize the 
alleles and to serve as alternative control in those instances where the normal epithelium 
ONA was not reliable or unavailable. ONA isolation was done as described previously (186). 
Microsatellite analysis 
LOH was assessed with the following polymorphic markers: 028405, 028423, 0281326, 
0281397, 048186, 048230, 048243, FGA, 058492, ACTBP2, 088258, 088298, 098152, 
098153, 098171, 098176, 098180, 098195, 098242, 098252, 098275, 098278, 
098283,098747,098752,0981816,0981826,0981851, 0108168, 0108169, 0108575, 
0108676, 01181776, 01184200, 0148267, 0148288, 0178695, 0178768, 0178960, 
018851,0228444,0228445,0228683,0228684,0228685, 0228686. Primer sequences 
were obtained from the Genome Oatabase (http://gdb.www.gdb.org/) or the Cooperative 
Human Linkage Consortium (http://lpg.nci.nih.gov/CHLC). In most cases ratios of upper and 
lower alleles were quantified using the Phosphor Imager (Molecular Oynamics, Sunnyvale, 
CAl. LOH was scored when the ratio between the upper and lower alleles in tumor ONA was 
<0.6 or >1.67 when compared with control ONA; (T1fT2)/(N1/N2) = ratio. Note that this 
distinguishes between losses of upper vs. lower allele. This representation was deemed 
necessary because of the observed alternate allele loss in some patients. A calculation of all 
losses shows that lower and upper alleles are lost with similar frequency. This indicates that 
our approach is valid because there is no preference for loss of, for instance, the upper, 
sometimes naturally weaker, allele. 
Results 
In a previous paper we describe the construction of genetic trees for the recurrent tumors of 
11 patients (Chapter 5). To this end we analyzed LOH of 46 microsatellite markers and 
performed mutation analysis of the FGFR3 gene. Hierarchical cluster dendograms were 
calculated based on these data. The cluster analysis demonstrated the clonal relation 
between the different tumors of a patient. The dendograms provided the starting point for the 
construction of genetic trees assuming that tumors with few aberrations precede those with 
many genetiC lesions. We established that in the trees the order of the tumors differs from 
the chronological order in which they appeared. Since, these trees reflect the actual history 
of genetiC tumor development they can be used to search for the first common genetic 
aberrations. In this study we focus on the development of LOH on chromosome 9q during 
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tumor evolution in order to gain more insight in the localization of possible tumor suppressor 
genes on this chromosome arm. Figure 1A shows the result of the partial genomic 
allelotyping for the 46 microsatellite markers. The exact number of tumors with loss for a 
certain marker is shown as the fraction of all informative tumors. Of the 17 chromosome 9 
markers shown, only D9S171 is located on 9p, all others are on 9q. On chromosome 9q, the 
loss is distributed across two regions, with a decrease in LOH around marker D9S176 (16%). 
The mean fractional allelic imbalance (FAI) on chromosome 9 is 47%, and this is about twice 
as high as the FAI on all other chromosomes combined (21 %)(Figure 18). This corresponds 
with results of others and appears to pOint in the direction of bladder cancer-specific 
alterations on this chromosome. However, a high frequency of loss was also found on 
chromosomes 10 (40% for D10S169) and 22 (44% for D22S683). For chromosome 2, there 
seems to be a difference between loss on the short arm (1 % and 6% for D2S423 and 
D2S405) and the long arm (28% and 39% for D2S1326 and D2S1397, respectively). 
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Figure 1. Aflelic imbalance in a partial aflelotype of 104 tumors. A, imbalance depicted per marker. Next to the 
bars, the number of tumors with loss is given as a fraction of the number of informative tumors. For chromosome 
9, alf markers are located on 9q, with the exception of marker 09S171, which is located on 9p. The markers are 
ordered from pter (top)-qter (bottom) for each chromosome, where relevant. B, Mean loss on chromosome 9 
compared to mean loss on other chromosomes. Every datapoint represents a marker. A horizontal bar indicates 
the mean loss. 
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Figure 2. (below and next page) Overview of the development of homozygosity on chromosome 9 in evolutionary 
trees based on whole genome typing. Every tumor is represented by an image of the status of chromosome 9. 
The arrows above the chromosomes indicate the branches of the trees that were deduced from accumulating 
genomic alterations. Only those tumors from each patient that have alterations on chromosome 9 are shown and 
only one example is shown in those cases where two or more tumors had identical changes. We included a 
hypothetical tumor of patients 12 and 48 to visualize a developmental step for reasons of clarity. On the left side 
of the images, the marker names are listed. Tumor names, year of removal and stage and grade are listed above 
the images. White blocks; retention of a marker, yellow; loss of the upper allele, blue; loss of the lower allele. 
gray; no signallnot done. red; microsatellite instability. Black bars on the left of the chromosome image emphasize 
the areas of homozygosity. 
12 
c:-- 0 _ , 
- , 
• • • " 
:U 
! 
i -- I * '" *m *~ DIS •• lI DlSNY * '" OI$"~ == 1 *'~ 
23 />:~ 
, 0 _ , , , • 
, . , 
" " " 
• 
" 
n 
" " " , ! I ! j ; , , 
0IStl1 
nnunn 
~," 
~~ 
_m 
-'" DIS'" 
_m 
- ., 
-= 
_ ,m 
35 
,--------.. [~ ~ 
F C ~ H _I ( 0 
'" III • 13 " •• III 
='" Ii _111 
=* DIoSl,· 1 
-~ 
_ 00 
OilS'" 
_,A 
_ro uuu 
22 /l~/~ 
0 , . , , 
• • " • • ! I j I I j 
-"I :1 n !I Ii 
=," 
=m 
00$"" 
~'" 
DOS7<1 
<ml l l 
~ '" 
=., 
~'" 
~,~ 
30 
~ ~ _ , _ 0 
0 
" " " " ! , j ! 
-'" ~ :~ I~ !~ -," _m l IIII"·S DSSW 
- ,g 
48 
C ( 0 f • 
C' .. Q III III 
I':! i! 'I I; !I Ii 
89 
Chapter 6 
61 63 
r1\\ \ 
L , (0 _ " I .. leo ii _ A 
17.a<a<"l7l13l11a~" 
~:~ I~ ~  !~ :~ I~ :~ !~ I~ I~ !~ 
80 
/\~ 
, ~ GAr 
~ 1\1 ~ • • 
-'" i§ -," ~" 
-005'l1li ' 
0lIS'~ 
=m 
= " 
='" uu 
85 
~~~ 
o C _ ~ _ G J _ A I ~ _ £ 
12 12 • .. • " III • 13 
From a gatekeeper tumor suppressor gene one would expect that it is inactivated in a 
substantial percentage of tumors from different patients and that its inactivation can be 
detected in the first step in tumor development. We therefore focussed on the build-up of 
chromosome 9q events in the genetic trees of 10 of the 11 the patients. One case, patient 
32, was omitted because in the six tumors that were investigated too few genetic aberrations 
were detectable to build a genetic tree. The constructed genetic trees provide the framework 
for Figure 2, in which the individual events that took place on chromosome 9 are illustrated . 
For reasons of clarity, only those tumors are depicted in which an additional 9q alteration 
occurred. 
Tumors with an LOH pattern that is identical to another tumor are omitted . For every 
tumor, the status of the informative markers along chromosome 9q is given. The arrows 
above each set of tumors indicate the evolutionary tree as deduced previously. The stage, 
grade and year of removal of the tumors are listed. For patient 30, for instance, we examined 
7 recurrences. All 7 tumors have lost the upper allele of 09S278. From tumor A, two different 
branches of the tree develop. In tumor G the LOH area around 0 98278 expands in size and 
an additional loss was observed for D9S1826. In the other branch , reflected by F and D, 
subsequent losses include D9S171 and D9S152. Thus, for patient 30, a putative 
chromosome 9q suppressor gene could be located in the region covered by marker 0 98278. 
In contrast, however, all 10 tumors from patient 12 show LOH for the lower allele of D9S752 
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and all tumors in the genetic tree derive from a hypothetical tumor that has lost this marker 
as its only genetic aberration. This hypothetical tumor clone is indicated in Figure 2 with a 
question mark. As can be seen in the Figure. two developmental lines lead to different 
additional areas of loss, in tumor M around marker 09S252 and in tumor G around marker 
09S152 and a second region around 09S747 and 09S195. Although not shown here, tumor 
G cannot have developed from M, based on the alterations found on other chromosomes. 
The two regions that are lost in tumor G are enlarged in the subsequent tumors F and E. 
Thus, for patient 12, a causative chromosome 9q gene could be located in the area marked 
by 09S752. 09S752 is also lost in all 6 tumors from patient 48, but all tumors also show loss 
for 09S180. These 3 patients, 30, 12 and 48, represent the only 3 of the 11 patients in which 
loss of a chromosome 9q marker was found in all tumors and/or was deduced to be the first 
or one of the first concomitant events in tumor formation. Loss of 9q markers was found for 
all other patients, but not in all tumors of a patient. Six patients (patients 22, 32, 61, 63, 80 
and 85) have one or more tumors without apparent loss on this chromosome arm. In total 13 
tumors were found without detectable LOH on 9q. These tumors are all situated in the early 
steps of the genetic trees. In addition, the genetic trees reveal that in the latter patients and 
in cases 23 and 35 loss of markers on other chromosomes precede a 9q event. A clear 
example in this respect is patient 61. All 15 tumors of this patient have lost the lower allele of 
D10S169. Losses on 9q apparently occur later and quite chaotically with alternate allele 
losses for several markers (Figure 2). From these results we conclude that LOH on 
chromosome 9q, although frequent, may not be a prerequisite for bladder cancer tumor 
formation. 
Discussion 
The majority of bladder cancers display losses of chromosome 9 sequences, irrespective of 
stage and grade. These investigations resulted in an accumulation of LOH data, finally 
leading to the suggestion that as much as 7 separate chromosome 9 tumor suppressor 
genes (3 on 9p and 4 on 9q) may contribute towards bladder cancer pathogenesis (33, 87, 
161, 186). Our data again show that alterations on chromosome 9q are very frequent and 
occur more often than losses on other chromosomes. This genomic distribution of LOH is in 
accordance with other studies on superficial pTa/pT1 bladder tumors, like the ones studied 
here. When the 9q LOH data for all 104 tumors studied in this work are added as was done 
in Figure 1A, one could, in analogy with the previous investigations, deduce that two regions 
of loss are observed on this chromosome arm. However, we have shown here that, taking 
into account the development of the losses, a completely different picture emerges. No 
common region of loss could be established in the early steps of the genetic trees in our 
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patients. Six out of 11 patients have one or more tumors without detectable LOH on 
chromosome 9q. This shows that LOH of 9q is not a prerequisite for bladder cancer initiation. 
In only 3 patients we have reason to believe that loss of a marker on chromosome 9q may be 
an early event. In two cases this concerned marker D9S752, which could indicate 
inactivation of a gene in that region, but in one of those two patients LOH is present at 
another region (D9S180) at the same time, which makes it difficult to determine the 
relevance of those regions. Moreover, the third patient has loss at marker D9S278, which 
again is at a completely different position on the long amn of chromosome 9. Therefore, the 
postulated early, or even initiating, loss of function of one or more tumor suppressor genes 
on chromosome 9q in bladder cancer pathogenesis is not supported by our data. The nature 
and apparent randomness of the mechanism that inflicts the regions of loss on chromosome 
9 is best illustrated by the finding that chromosome 9q can be the target of as much as 10 
independent LOH events in one patient (23 and 61) and by patients in which some tumors 
show loss of alternate alleles. 
Studying bladder cancer gives us the possibility to monitor the LOH in multiple 
recurrences over time. This is an important advantage in understanding the role of LOH in 
tumorigenesis. Loss of heterozygosity analyses have been performed since the discovery of 
the first tumor suppressor gene and a comprehensive list of deleted chromosome regions 
has been made for most tumor types. Despite the apparent straightforwardness of this 
method, the number of actual genes isolated in this way is disquietingly scarce. The regions 
where PTEN (102) and DPC4 (65) are located, do display LOH in tumor types like 
glioblastomas, prostate and breast cancer, and pancreatic and colorectal cancer, however, 
the genes were cloned only because of the identification of homozygous deletions. Bladder 
cancer is not the only tumor type where confusing LOH results have led to the assumption 
that multiple closely spaced tumor suppressor genes exist on one chromosome (53, 99, 
131), and chromosome 9 is not even the only chromosome in bladder cancer where this 
phenomenon has been observed (195). Considering the many tumor types with a similar 
patchwork LOH pattern, we feel that it is rather unlikely that multiple tumor suppressor genes 
for a certain type of cancer all reside on one chromosome (arm). Comparative mapping of 
the mouse genome shows that human chromosome 9q is spread out over 3 different mouse 
chromosomes. Moreover, it is difficult to envisage an evolutionary advantage for man to 
cluster tumor genes on one chromosome in order to induce cancer more easily. In our view, 
most of the LOH events will be due to random genomic instability. Thus, even if some of 
these losses target growth-inhibiting genes, the localization of the relevant gene is severely 
hampered by the enormous background of random genetic events. We think it therefore 
unlikely that a bladder cancer gatekeeper gene on chromosome 9q, if present, will be 
identified through LOH analysis alone. Perhaps the higher frequency of LOH events on 
Variable 9q losses 
chromosome 9 when compared to the other chromosomes even has a mechanistic rather 
than a tumor promoting reason. In this respect it is relevant to mention that chromosome 9, 
together with 1 and 16, is one of the 3 chromosomes with a large heterochromatin region. It 
has been suggested that heterochromatin is involved in specific forms of chromosomal 
instability (178, 206). Although this is speculative, it is therefore not impossible that the 
frequent alterations on chromosome 9 are due to such a chromosomal instability mechanism 
for which chromosome 9 is extremely sensitive and that the elusive gatekeeper gene may 
not reside on this chromosome after aiL 
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General Discussion 
Aim of this thesis 
Bladder cancer is a frequently occurring disease with many different histopathological forms. 
These different phenotypes are thought to refiect a heterogeneous collection of genotypes, 
and, perhaps, pathways along which bladder cancer might develop. The identification of the 
genetic alterations in carcinoma of the bladder is therefore considered pivotal in our 
understanding of the pathogenesis of the disease and will be helpful in designing improved 
strategies for prevention, diagnosis, prognosis, and therapy. This thesis focusses on 
identification of the alterations (especially on chromosome 9q) in transitional cell carcinomas. 
The results will be discussed in a wider context, and also suggestions for future research will 
be made. 
No correlation between underrepresentation of chromosome 9 and LOH 
Aberrations concerning chromosome 9 are found in TCCs of all grades and stages, and 
sometimes it is the sole abnormality seen. We therefore started the work described here with 
the classical hypothesis that this chromosome harbors a gatekeeper gene for bladder 
cancer. Consequently, it should be possible to localize this gene by mapping of the deletions 
on this chromosome in tumors. A combination of previous LOH, FISH and CGH results led to 
the interpretation that monosomy of chromosome 9 may occur in over 50% of the TCCs of 
the bladder. Tumors that have lost an entire copy of chromosome 9 cannot be used to map a 
TSG. We therefore decided to analyse all tumors first with in situ hybridization (ISH) and use 
only those with 2 copies of chromosome 9 for LOH analysis (Chapter 2). However, with ISH, 
complete monosomy for chromosome 9 was observed in only 1 of 40 tumors. Four other 
tumors had subpopulations of cells with only one chromosome 9. A rescreen of the literature 
revealed that a tumor is already labeled as having monosomy for chromosome 9 when as 
low as 20% of the cells have lost this chromosome. Moreover, we found that relative loss of 
chromosome 9 (relative to chromosome 6) does not always coincide with LOH for 
chromosome g. This can be explained by assuming that relative loss of 9 in a, for instance, 
tetraploid tumor may reduce the chromosome 9 copy number from 4 to 3 or 2. However, both 
paternal and maternal copies can still be present and no actual loss of genomic material 
exists. Although an association was found between chromosome 9 underrepresentation and 
LOH, the extent of loss in the LOH analyses was much more pronounced than can be 
explained by the extent of underrepresentation. This can be explained by partial or interstitial 
deletions without the loss of the centromere of chromosome 9. We therefore conclude that 
underrepresentation of chromosome 9 does not necessarily lead to the inactivation of the 
postulated TSG. The LOH analyses further revealed that several tumors had more than one 
region of loss on 9 and confirmed that only 1 tumor had lost an entire copy of this 
chromosome. We then decided to map the LOH regions in further detail. 
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Many candidate regions but no mutant genes 
To narrow the localisation of one or more putative tumor suppressor genes on chromosome 
9 that playa role in TCC of the bladder, we examined tumors with a panel of microsatellite 
markers along the chromosome (Chapter 3). We found evidence for two different loci on the 
long arm of chromosome 9 where potential tumor suppressor genes are expected. These loci 
are delineated by interstitial deletions in two bladder tumors. Both regions were examined for 
homozygous deletions with EST and STS markers, but no homozygous deletions were 
observed in 17 different bladder tumor cell lines. 
Because of the difficulty in narrowing down the smallest region of overlap (SRO), we 
decided to look for possible candidate genes in the regions known to be lost at that moment. 
In Chapter 4, the mutation analysis of the Kruppel-like zinc finger gene ZNF189, the 
Tuberous Sclerosis Complex gene 1 (TSC1) and the TGF beta receptor type I (TGFBR1) in a 
series of bladder tumors and bladder tumor cell lines is described. All three genes have been 
mapped to 9q regions commonly deleted in transitional cell carcinoma of the bladder. Our 
study excludes an important contribution from the ZNF189, TSC1 and TGFBR1 genes. We 
investigated the frequency of the 6A allele of the polyalanine tract present in exon 1 of the 
TGFBR1 gene since it was suggested that the protein with a shorter alanine tract (6A) is less 
active in signal transduction than the most frequent 9A allele. This would provide a logical 
explanation for the association of the 6A allele with cancer predisposition. We found no 
evidence to support a role for the 6A allele in bladder cancer susceptibility. In contrast, we 
found higher percentages for both bladder cancer (17 vs. 13%) and control (17 vs. 10.6%) 
groups. It is not clear how the discrepancy between their and our findings can be expla·lned. 
At this moment, combined LOH analyses in bladder cancer show a multiplicity of 
events suggesting to some authors that chromosome 9q might harbor 2, 3 or even 4 genes 
that may have a role in bladder cancer. Several candidate genes have been included in 
mutation analysis, besides the ones tested here. So far, none of these genes shows a 
significant number of alterations in bladder tumors. 
Mitotic recombination as an explanation for multiple LOH events 
The finding of multiple regions of LOH on chromosome 9 raises the question whether all 
these regions are indeed harboring relevant TSGs. We therefore decided to investigate 
multiple bladder tumors from a limited number of patients in order to investigate the 
development of the genetiC aberrations in time. If there is a gatekeeper gene on 
chromosome 9, alterations around the location of this gene would be expected early in the 
disease and stay present throughout. In Chapter 5, we describe the reconstruction of bladder 
tumor development in individual patients spanning periods of up to 17 years. Genomic 
alterations detected in the tumors were used for hierarchical cluster analysis of tumor 
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subclones. The cluster analysis highlights the clona[ relationship between tumors from each 
patient. Based on the cluster data we were able to reconstruct the evolution of tumors in a 
genetic tree, where tumors with few aberrations precede those with many genetic insults. 
The sequential order of the tumors in these pedigrees differs from the chronological order in 
which the tumors appear. Thus, a tumor with few alterations can be occult for years following 
removal of a more deranged derivative. Extensive genetic damage is seen to accumulate 
during the evolution of the tumors. We also observed a very variable loss pattern in tumors of 
the same patient, with many small and expanding regions of loss of heterozygosity. To 
explain the extent of genetic damage in combination with the low stage and grade of these 
tumors, we hypothesize that in bladder cancer pathogenesis an increased rate of mitotic 
recombination is acquired early in the tumorigenic process. This type of damage to the 
genome is without actual loss of genetic material, more consistent with the mostly diploid 
tumors. 
A second look at chromosome 9q LOH: multiple recurrent bladder cancers 
The first allelotyping studies involved two or three markers on every chromosome arm. Loss 
of these markers swiftly led to the conclusion that a whole arm was deleted, or that a tumor 
showed monosomy for an entire chromosome. When, in subsequent studies, more markers 
were included, more (interstitial) deletions were detected and used to define the SRO. This is 
a valid method, as long as tumors are compared with an identical genetic background 
(caused by inactivation of the same gatekeeper gene). In bladder cancer, this is difficult since 
it has been suggested that there is a genetic difference between superficial recurrent cancer 
and more invasive cancer, although the histopathological distinction is not always clear and 
both presumed types show LOH on the same chromosome. Thus, in pooling these different 
tumor types there is a risk that a specific alteration will be obscured. Furthermore, some 
tumors appear to have more than one region of deletion on the same arm and therefore they 
cannot and should not be used to delineate a possible gene locus, since the relevance of the 
different regions to one another cannot be determined. The interpretation of LOH results is at 
best very complicated when four genes are suspected on the same chromosome arm, and 
seven on the chromosome in total. In our study, the ongoing process of multiple alterations 
on chromosome 9 is elucidated by deletion mapping in multiple recurrent bladder cancer. In 
Chapter 6, we describe the genesis and development of chromosome 9 alterations within 11 
patients with multiple superficial bladder cancer. We show that loss of heterozygosity on this 
chromosome is almost never the characteristic first step. The regions of loss are multiple and 
variable in different tumors of the same patient and expand over time. This, we believe, 
makes it unlikely that a bladder cancer gatekeeper gene on chromosome 9q, if present, will 
be identified through LOH analysis alone. 
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Future directions 
The patchwork LOH pattern and the increase in LOH during tumor development in mostly 
diploid superficial papillary bladder tumors might be due to an increased frequency of mitotic 
recombination. Future research should focus on trying to find proof for this hypothesis. 
Patients with Bloom's syndrome, an autosomal recessive disorder characterized by growth 
deficiency; sun-sensitive skin, predisposition to malignancy, and chromosomal instability, 
exhibit an increased recombination between homologous chromosomes and between sister 
chromatids. The high sister chromatid exchange (SCE) is a diagnostic feature of the disease. 
It will therefore be interesting to determine the rate of SCE in bladder tumors as well. In order 
to do so, it would be favorable to propagate these small sized tumors ;n vnro, because the 
tumor cell lines in use today are mainly derived from invasive, aggressive tumors and these 
may not reflect an accurate genetic representation of superficial tumors. Another possibility is 
to search for mutations in the gene mutated in Bloom's syndrome, BLM. This gene encodes 
a DNA he!icase involved in unwinding DNA to make it available for replication and repair. 
Furthermore, the number of alterations on chromosome 9 is clearly higher than on other 
chromosomes. Maybe this represents a chromosome breakage defect, like in Bloom's 
syndrome or Fanconi's anemia. These syndromes are known as nonspecific chromosomal 
breakage syndromes. Conversely, the ICF syndrome (Immunodeficiency - Centromeric 
instability - Facial anomalies) only shows instability of chromosomes 1, 9 and 16. These 
chromosomes differ in this respect that they have a large pericentromeric heterochromatin 
area. Mutations in the DNMT38 gene, encoding DNA methyltransferase 3B cause 
undermethylation of classical satellites II and JlI, which are present in this heterochromatin. 
This makes the heterochromatin more susceptible to breakage. It is possible that a similar 
phenomenon is operating in bladder cancer. Therefore, next to mutation analysis of the 
DNMT38 gene, it will be worthwhile to test this hypotheSis by determining the methylation 
profile of the 9q heterochromatin region in bladder tumors. 
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Samenvatting 
Blaaskanker is in Nederland de zesde meest voorkomende vorm van kanker. Jaarlijks krijgen 
zo'n 2550 mensen blaaskanker en zullen er ongeveer 1200 aan overlijden. De meeste 
mensen krijgen een relatief onschuldige, oppervlakkige tumor die met behulp van een 
transurethrale resectie kan worden verwijderd. Kenmerkend is dat na verwijdering van deze 
oppervlakkige tumoren, meer dan 70% van de patienten een of meerdere recidieven 
ontwikkelt, die meestal oak oppervlakkig zijn. Blaaskanker is, door de veelvuldige 
recidivering, uitermate geschikt om als model te dienen voor het bestuderen van de 
tumorevolutie binnen een patient. Het ontstaan en de progressie van tumoren naar meer 
invasief gedrag wordt toegeschreven aan een opeenstapeling van genetische afwijkingen in 
tumor suppressor genen (TSGs) en oncogenen. Moleculair genetisch onderzoek van kanker 
heeft als doe! deze genen op te sporen en door de analyse van hun bio[ogische functie 
inzicht te verkrijgen in de regu!atie mechanismen die in de kankercel zijn veranderd. Verlies 
van een specifiek chromosomaal gebied, aantoonbaar via LOH (!oss of heterozygosity) 
analyse, wordt vaak gebruikt am de plaats van TSGs te bepalen. In blaaskanker wordt de 
meeste LOH gevonden op chromosoom 9, waardoor men veronderstelt dat op dlt 
chromosoom een TSG moet liggen dat blaaskanker veroorzaakt. 
Het doel van het in dit proefschrift beschreven onderzoek was om te bepalen wat het 
belang is van LOH in het algemeen en chromosoom 9 in het bijzonder in de pathogenese 
van blaaskanker. Hiertoe werd in eerste instantie in 40 blaastumoren het aantal 
chromosomen 9 bepaald met verschillende technieken, zoals in situ hybridisatie en LOH 
analyse. Dit is beschreven in hoofdstuk 2. Alhoewel 18 blaastumoren verhoudingsgewijs 
weinig chromosomen 9 bleken te hebben, was er maar een tumor die compleet ver!ies van 
een van beide kopieen had. In 5 van deze 18 tumoren kon de onderrepresentatie van dlt 
chromosoom niet worden bevestigd door LOH analyse. Hieruit kan worden geconc!udeerd 
dat een verlies van chromosoom 9 zoals aangetoond met in situ hybridizatie niet gerelateerd 
hoeft te zijn aan het verlies dat wordt aangetoond door LOH analyse. Uit de LOH analyse 
bleek verder dat meerdere tumoren meer dan een gebied verloren hadden op chromosoom 
9. Daarom werd besloten deze gebieden verder in kaart te brengen. 
In hoofdstuk 3 wordt beschreven hoe met LOH analyse is geprobeerd te bepalen 
welk specifiek deel van chromosoom 9q veri oren is gegaan. Onze resultaten onderschreven 
de hypothese dat er twee verschillende gebieden van verlies ziJn, wat zou kunnen betekenen 
dat er twee verschillende TSGs op de lange arm liggen. De gebieden, genaamd TCC1 en 
TCC2, zijn getest in 17 blaastumor cellijnen op de aanwezigheid van homozygote deleties, 
maar deze werden niet gevonden. Oit kan betekenen dat deleties in deze gebieden zo klein 
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zijn dat ze moeilijk op te sporen zijn, of dat de genen in deze gebieden niet snel worden 
uitgeschakeld door een homozygote deletie. Overigens zijn door anderen nog meer 
gebieden van verlies op chromosoom 9 gevonden, zodat het totale aantal wordt geschat op 
vier gebieden op de lange arm en drie gebieden op de korte arm. Het is echter de vraag of 
het waarschijnlijk is dat al deze gebieden een voor blaaskanker relevant TSG bevatten. 
Aangezien de TCC1 en TCC2 gebieden niet verder verkleind konden worden, 
hebben we gekozen voor mutatie analyse van de kandidaat TSGs ZNF189, het tubereuze 
sclerose complex gen 1 (TSC1) en de TGF beta receptor type I (TGFBR1). Deze liggen aile 
drie op chramosoom 9q in die gebieden die vaak veri oren gaan in blaastumoren. Analyse 
van deze genen toonde verschillende polymorfismen en mutaties aan in ZNF189 en TSC1, 
maar niet in het TGFBR1 gen (hoofdstuk 4). In exon 1 van het TGFBR1 gen is een 
polyalanine stretch aanwezig met een variabele lengte. De meest voorkomende lengtes zijn 
6 of 9 alanines. Er zijn aanwijzingen dat het allel met 6 alanines (6A) vaker voorkomt bij 
patienten met bepaalde vormen van kanker. Om dit te onderzoeken, hebben we de lengte 
van de stretch bepaald in een graep patienten met blaaskanker en een contrale graep. In 
beide groepen was het percentage heterozygoten (6A19A) 17%. Het lijkt er dus op dat het 6A 
allel in blaaskanker geen rei van betekenis speelt. Behalve de drie door ons onderzochte 
genen, zijn nog veel meer genen op chromosoom 9 getest op de aanwezigheid van mutaties. 
In veel van die genen wordt we! eens een mutatie gevonden, maar tot nu toe is er geen 
enkel gen gevonden met mutaties in een significant aantal blaastumoren. 
De vee!voud aan lOH gebieden en het gebrek aan mutaties in kandidaatgenen, geeft 
aanleiding te den ken over andere mechanismen waarmee lOH tot stand kan komen. Oit 
bracht ons op het idee om de ontwikkeling van deze gebieden te vo!gen in meerdere 
opeenvolgende tumoren van een klein aantal patienten. De blaastumoren zijn verzame!d van 
een groep patienten die tot 15 recidieven hadden gekregen in de loop van 6 tot 17 jaar tijd. 
Met LOH analyse zijn de genetische afwijkingen van deze tumoren bepaald. Hieruit bleek dat 
de verschillende recidieven van eenzelfde patient clonaal aan elkaar gerelateerd waren en 
dus U'lt elkaar, of uit gemeenschappelijke voorlopertumoren moeten zijn ontstaan. De 
moleculaire evolutie van de aandoening kon met behulp van clusteranalyse worden 
gereconstrueerd in de vorm van een genetische stamboom, waarbij elke vertakking een 
nieuwe afwijking representeert. Aan de hand van deze stamboom kon worden 
geconcludeerd dat de volgorde waarin de tumoren zich ontwikkelen binnen een patient sterk 
kan afwijken van de volgorde waarin ze in de kliniek worden ontdekt. De tumorevolutie staat 
beschreven in hoofdstuk 5. Opmerkelijk was verder de grote toename in het aantal 
afwijkingen dat werd gevonden binnen een stamboom, wat suggereert dat deze 
blaastumoren genetisch instabiel zijn. Uit eerdere anderzoeken is echter gebleken, dat 
oppervlakkige blaastumoren meestal een redelijk nonmale hoeveelheid DNA bevatten (ze zijn 
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diploTd). Een mogelijke verklaring v~~r deze bevindingen is dat de genetische afwijkingen 
worden veroorzaakt door een verhoogde mitotische recombinatie frequentie aangezien dit 
een gebeurtenis is waarbij geen genetisch materiaal verloren gaat, maar wei LOH optreedt. 
Met de informatie die deze studie heeft opgeleverd is ook duidelijk geworden dat de 
rol van TSGs op chromosoom 9 in het ontstaan van b!aaskanker wordt overschat. In 
hoofdstuk 6 wordt beschreven hoe de afwijkingen aan chromosoom 9q zich binnen patienten 
ontwikkelen. De afwijkingen treden in de meeste patienten pas in een later stadium op en 
zijn dus niet de karakteristieke eerste gebeurtenis in het ontstaan van de tumor. Daarnaast 
zijn de gebieden van verlies variabel binnen de tumoren van een patient en worden ze in de 
loop van de tijd groter. Het aantal afzonderlijke gebeurtenissen kan in sommige patiemten 
zelfs oplopen tot tien. Tenslotte varieert de plaats van de verloren gebieden ook nog tussen 
de patienten. Hierdoor wordt de hypothese dat dit chromosoom een, voor blaaskanker, 
belangrijk gen bevat minder waarschijn!ijk. 
Ais de vele gebieden van LOH in blaaskanker inderdaad worden veroorzaakt door 
een verhoogde mitotische recombinatie frequentie, is het interessant om dit in een 
vervolgstudie te onderzoeken. Oit is onder meer moge[ijk door het niveau van recombinatie 
tussen zusterchromatiden vast te stellen (sister chromatid exchange, SCE). Oit is een maat 
voor de totale recombinatie frequentie en wordt als zodanig ook toegepast bij patienten met 
het syndroom van Bloom. Deze patienten hebben een verhoogd risico op het krijgen van 
kanker door een gebrekkig hersteJ van fouten in hun DNA. Oaarnaast is blaaskanker niet het 
enige tumor type waarbij meerdere gebieden van verlies op een chromosoom arm worden 
gevonden. Het is interessant om te onderzoeken of aan dit verschijnsel bij andere typen 
tumoren ook een verhoogde mitotische recombinatie frequentie ten grondslag ligt. Oit zou 
ook een verk!aring kunnen bieden voor het feit dat LOH analyse aileen nog niet succesvol is 
geweest in het cloneren van TSGs. Tot slot kan het mogelijk zijn dat de vele afwijkingen op 
chromosoom 9 in blaaskanker duiden op een chromosoom specifieke instabiliteit. Oit is 
bijvoorbeeld het geval in het ICF syndroom. Hierbij zijn aileen chromosoom 1, 9 en 16 
aangedaan. Deze chromosomen verschillen van de andere doordat ze onder het centromeer 
een groot heterochromatine gebied hebben. ICF wordt veroorzaakt door mutaties in het 
methyltransferase gen DNMT3B, waarna het heterochromatine te weinig gemethyleerd 
wordt. Hierdoor wordt het gevoeliger voor breuken. Misschien is er in blaaskanker iets 
vergelijkbaars aan de hand. 
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